REPUBLIC OF CYPRUS

MINISTRY OF HEALTH

1448 NICOSIA

Cyprus Cancer Registry (CyCR)

Progress Report

August 2016

(Data 2011-2013)

Prepared by:

Dr. Pavlos Pavlou

Anna Demetriou

Cyprus Cancer Registry
Health Monitoring Unit
Ministry of Health
1 Prodromou Street & 17 Chilonos Street
1448 Lefkosia
Cyprus

Tel.: +357 22 605457
Fax: +357 22 772238
Website: http://www.moh.gov.cy

Data accessed: 01 September 2016

Documents:

This document: ..\CyCR_Progress Report 2016*CyCR_Progress Report 2016_v07.docm*

CANREG ANALYSIS.xlsm

CHILDHOOD_INCIDENCE_01.xlsm

Childhood Cancer.xlsm.lnk

CyCR FREQUENCY TABLES 2012-09-20.doc

Contents

CYPRUS CANCER REGISTRY (CyCR)

Progress Report 2016

This Report describes the main activities of the Cyprus Cancer Registry (CyCR) during 2016. In this year, we completed data entry and quality checks for cancer cases incident in 2013. The Report is in line with the structure proposed by MECC. We have included a number of additional tables and graphs that may be useful to some readers.

a) Hiring of new staff

There were no staff changes since the last report of 2011.

Registry Staff

- Dr. Pavlos Pavlou, Director of Operations and MECC Principal Investigator (part-time).
- Ms. Anna Demetriou, Statistician (part-time).
- Ms. Christiana Soteriou, Office Cancer Registrar (full-time).
- Ms. Koula Lysandridou, Itinerary Cancer Registrar (full-time).
- Ms. Maria Kleridou, Itinerary Cancer Registrar (full-time).

b) Purchasing of new equipment

Two new desktop computers and one laptop were purchased in 2016, by the Department of Information Technology Services for the Health Monitoring Unit. These are being used by the cancer registry director of operations, the statistician and the office registrar.

c) Training

There was no formal training for the staff in 2016.

d) Data collection

We carried on with the usual casefinding, abstraction, resolution and deletion procedures as in previous years. We continued our cooperation with the Bank of Cyprus Oncology Centre in exporting and importing **electronic data** for 2013, 2014, 2015 and 2016. Most of the demographic fields and some clinical fields, including first **radiotherapy** and date, were imported successfully. Electronic imports involved BOCOC cases admitted up to August 2016.

BOCOC staff prepared Excel files according to a specified data structure. These were imported into Access. We cleaned the data and converted some of the text fields to coded format. The spelling of names in BOCOC files, now conforms with the Romanic standard of transliteration that is used by CanReg4. This improves the ability of our system to identify duplicate persons. Data are processed in Access and then exported to a text file suitable for importing. We use the import facility of CanReg4.

The electronic case records are imported as '**pending'**. They are checked and 'confirmed', case by case by the cancer registrars. Whenever necessary, the principal investigator is consulted. This data import procedure has saved a lot of typing and has also helped to avoid typing mistakes.

Since 2012 we are able to import **chemotherapy, hormone therapy and immunotherapy** data from the BOCOC database.

First surgery with dates is not systematically recorded in the clinical notes or the electronic files of BOCOC. These data were abstracted from all available paper clinical records as best we could.

The **main benefit** of electronic data transfer is improvement in completeness and quality of data. It does not seem to have made a major improvement in speed of cancer registration. Most of the delays occur during casefinding procedures and while the office registrar reads the entries in histology reports and other clinical records in order to assign the correct topography, morphology, summary staging, differentiation, tumour sequence and date codes. This is because most of BOCOC's tumour data, with exception of diagnosis and TNM staging, are not coded. Some are recorded electronically as text. Furthermore, BOCOC's diagnosis codes are based on ICD-10. There is no systematic separate coding for topography or morphology. It is therefore, not possible to do direct electronic transfer of diagnoses with ICD-O-3 topography and morphology codes. We import them as text and the office registrar assigns the appropriate ICD-O-3 codes manually. The same applies to staging and grade/differentiation data.

We have not yet been able to electronically import data from the **public hospital discharge files**. In 2016 we had the usual difficulties in getting the data we need.

We continued importing **Death Certificate Notified** cases. They were imported from the electronic Causes of Death Database that was created in 2004 by the Health Monitoring Unit. Most of the death data before 2004, are only available in electronic files obtained from the Ministry of Interior. Original copies of these old death certificates are not easily available. Therefore, the accuracy of certification and coding of deaths before 2004 cannot be assessed.

In 2016 we imported all death records having cancer as the underlying cause of death or cancer mentioned as one of the multiple causes. The death records were imported as **pending.** They were individually checked and confirmed by the office registrar. This procedure has made a significant improvement in the completeness of cancer registration but the percentage of DCO cases for 2004-2013 is quite high, at around 8.7 % of all incident cases. The cancers with the highest percentage of DCO cases are shown in CyCR Table viii, page 13. Unfortunately, **follow-back** for these cases is time consuming, and inefficient.

By using the dates of death for non cancer deaths we have improved the recording of follow-up data that are necessary for calculating cancer survival. Death records were imported irrespective of whether they had a matching national ID in the Cancer Registry. Any person duplicates were identified by using the 'person check' facility of CanReg4.

The well established process of recording **resident addresses** in coded format, that were introduced in 2009, were sustained in 2016. We now use a coded list of all the streets in the government controlled areas of Cyprus. This list is included in our CanReg4 dictionary. Updates, supplied by the Post Office at 3 monthly intervals, are used to update our dictionary. This has made the recording of residence much more accurate and consistent. The original address text data are kept in the data base.

The field for **occupation** was modified to facilitate data entry. We now use the latest International Standard Classification of Occupations (ISCO-08). The completeness of the occupation field is quite low, at around 40-50%, mainly because it is not always recorded in the clinical notes. There is also a significant proportion of unspecified occupations such as 'housewife' or 'retired'. As a result, the usefulness of this field is limited. However, one cannot exclude the possibility of using it for research in the future.

Some of the fields that were previously recorded as text, such as the histologist fields, have been converted to coded fields.

We are planning to transfer all the data of the Cancer Registry from CanReg4 to CanReg5 before the end of 2016. Despite several attempts to do this in the past, we could not make a full transfer of all the data,

including the pending cases. We believe the current database in CanReg4 needs some corrections regarding the unique identifiers of a small number of cancer patients in order to facilitate the accurate transfer of the data.

The following tables show some useful statistics mainly for the period 2011-2013. Some of the figures showing trends include data from 1998 to 2013.

CyCR Table i. Sources used for casefinding and abstraction, 2011-2013

Type of Source	Source Names	Public Sector	Private Sector
Histopathology Laboratories	Lefkosia GH, Private Laboratories	1	5
Cytology Department	Lefkosia GH	1	
Bone Marrow Registry	Lefkosia Makarios Hospital	1	
Pediatric Oncology Dep/ts	Lefkosia Makarios Hospital	1	
Hematology Departments	Lefkosia GH, Lemesos GH	2	
Oncology Departments	Lefkosia GH, Lemesos GH and BOCOC (Hospital Records)	2	1
Surgical Theatre Logbooks	Lefkosia GH and Lemesos GH (General Surgery)	2	
Private Doctors	About 110 private doctors have notified cancer cases.		110

CyCR Table ii. Cases by type of facility as main source of data, 2011-2013

Record status	Confirmed
Behaviour	Malignant

Facility type	2011		2012		2013		Total	
	Count	%	Count	%	Count	%	Count	%
Hospital	3050	90.3%	3075	92.4%	3078	93.4%	9203	92.0%
Clinic	112	3.3%	78	2.3%	74	2.2%	264	2.6%
Hospice	12	0.4%	9	0.3%	3	0.1%	24	0.2%
Unknown	204	6.1%	167	5.0%	142	4.3%	513	5.2%
Total	3378	100.0%	3329	100.0%	3297	100.0%	10004	100.0%



CyCR Table iii. Cases by healthcare sector by year, 2011-2013

RecST Confirmed
BehaT Malignant

Health Sector	2011		2012		2013		2011-2013	
	Count	%	Count	%	Count	%	Count	%
Private	2169	64.2%	2127	63.9%	2139	64.9%	6435	64.3%
Public	1005	29.8%	1035	31.1%	1016	30.8%	3056	30.5%
Unknown	204	6.0%	167	5.0%	142	4.3%	513	5.1%
Total	3378	100.0%	3329	100.0%	3297	100.0%	10004	100.0%



CyCR Table iv. Cases by district of main source of data by year, 2011-2013

Record status: Confirmed
Behaviour: Malignant

District	2011		2012		2013		Total	
	Count	%	Count	%	Count	%	Count	%
Lefkosia	2451	72.6%	2466	74.1%	2440	74.0%	7357	73.5%
Lemesos	420	12.4%	421	12.6%	431	13.1%	1272	12.7%
Pafos	140	4.1%	140	4.2%	144	4.4%	424	4.2%
Larnaka	109	3.2%	85	2.6%	90	2.7%	284	2.8%
Ammochostos	18	0.5%	29	0.9%	19	0.6%	66	0.7%
Unknown	240	7.1%	188	5.6%	173	5.2%	601	6.0%
Total	3378	100.0%	3329	100.0%	3297	100.0%	10004	100.0%



CyCR Table v. Cases by hospital / clinic as main source of data, 2011-2013

Record status: Confirmed
Behaviour: All, incl. in situ

PH = Private Hospital
PC = Private Clinic

	2011		2012		2013		2011-2013	
Hospital Name	Count	%	Count	%	Count	%	Count	%
BOCOC	1955	56.1%	1989	58.1%	1979	57.8%	5923	57.3%
Lefkosia General Hospital	479	13.8%	469	13.7%	480	14.0%	1428	13.8%
Lemesos General Hospital	305	8.8%	345	10.1%	328	9.6%	978	9.5%
Pafos General Hospital	89	2.6%	110	3.2%	113	3.3%	312	3.0%
Larnaka General Hospital	115	3.3%	85	2.5%	93	2.7%	293	2.8%
Lemesos PH 1	98	2.8%	74	2.2%	100	2.9%	272	2.6%
Makario Nosokomio Lefkosia	30	0.9%	29	0.8%	21	0.6%	80	0.8%
Pafos PC 02	24	0.7%	22	0.6%	22	0.6%	68	0.7%
Lefkosia PH 4	21	0.6%	14	0.4%	20	0.6%	55	0.5%
Ammochostos Hospital	14	0.4%	22	0.6%	17	0.5%	53	0.5%
Lefkosia PH 2	17	0.5%	16	0.5%	20	0.6%	53	0.5%
Lefkosia PC 3	12	0.3%	12	0.4%	3	0.1%	27	0.3%
Pafos PC 03	14	0.4%	8	0.2%	3	0.1%	25	0.2%
Arodafnousa	12	0.3%	9	0.3%	3	0.1%	24	0.2%
Kyperounta Hospital	8	0.2%	5	0.1%	7	0.2%	20	0.2%
Lemesos PC 25	8	0.2%	4	0.1%	8	0.2%	20	0.2%
Ammoch. PC 1	4	0.1%	7	0.2%	2	0.1%	13	0.1%
Pafos PC 01	7	0.2%	1	0.0%	3	0.1%	11	0.1%
Pafos PC 08	3	0.1%	1	0.0%	3	0.1%	7	0.1%
Larnaka PC 1	2	0.1%	1	0.0%	3	0.1%	6	0.1%
Pafos PC 10	2	0.1%	1	0.0%	3	0.1%	6	0.1%
Lefkosia PC 8					5	0.1%	5	0.0%
Pafos PC 04	2	0.1%			3	0.1%	5	0.0%
Pafos PC 05	2	0.1%	2	0.1%	1	0.0%	5	0.0%
Lemesos PC 23	4	0.1%					4	0.0%
Pafos PC 16	2	0.1%			1	0.0%	3	0.0%
Lefkosia PH 3	2	0.1%					2	0.0%
Lemesos PC 24	1	0.0%	1	0.0%			2	0.0%
Larnaka PC 3					1	0.0%	1	0.0%
Larnaka PC 4			1	0.0%			1	0.0%
Lefkosia PC 16			1	0.0%			1	0.0%
Lefkosia PC 4	1	0.0%					1	0.0%
Lemesos PC 19	1	0.0%					1	0.0%
Lemesos PC 2			1	0.0%			1	0.0%
Lemesos PC 22					1	0.0%	1	0.0%
Lemesos PC 4	1	0.0%					1	0.0%
Lemesos PC 6	1	0.0%					1	0.0%
Pafos PC 12	1	0.0%					1	0.0%
UNKNOWN	245	7.0%	192	5.6%	181	5.3%	618	6.0%
Total	3482	100.0%	3422	100.0%	3424	100.0%	10328	100%


CyCR Table v. Cases by hospital / clinic as main source of data, 2011-2013
Lemesos PH 1 3%
All others 5%
Unknown 6%
Larnaka General Hospital 3%
Pafos General Hospital 3%
Lemesos General Hospital 9%
Lefkosia General Hospital 14%
BOCOC 57%

CyCR Table vi. Number and % of cases by basis of diagnosis by year, 2011-2013

Record status: Confirmed

Behaviour: All, including in situ

Basis of diagnosis	2011		2012		2013		Total	
	Count	%	Count	%	Count	%	Count	%
Death Certificate only	280	8%	244	7%	241	7%	765	7.4%
Microscopic verification	3182	91%	3148	92%	3155	92%	9485	91.8%
Non-Microscopic verification	14	0%	19	1%	17	0%	50	0.5%
Unknown	6	0%	11	0%	11	0%	28	0.3%
Total	3482	100%	3422	100%	3424	100%	10328	100%



CyCR Table vii. Percentage of cases by basis of diagnosis by year 2007-2013

Record status Confirmed

Behaviour All, Including in situ

Basis of diagnosis	2007	2008	2009	2010	2011	2012	2013	2007-2013
0-Death Certificate only	9.6%	8.2%	6.9%	8.3%	8.0%	7.1%	7.0%	7.9%
1-Clinical	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%
2-Clincal Investigation	1.1%	0.8%	0.8%	0.5%	0.4%	0.5%	0.4%	0.6%
3-Surgery/Autopsy		0.0%						0.0%
5-Cytology/Haematology	3.4%	2.4%	3.1%	2.4%	2.2%	2.1%	1.7%	2.5%
6-Histology of Metastases	3.8%	2.8%	2.6%	2.7%	2.3%	2.9%	2.7%	2.8%
7-Histology of Primary	81.9%	85.5%	86.3%	85.7%	86.8%	87.0%	87.7%	85.9%
8-Autopsy and Histology		0.0%						0.0%
9-Unknown	0.2%	0.1%	0.2%	0.4%	0.2%	0.3%	0.3%	0.2%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%





CyCR Table viii. Number and Percentage of DCO cases by IARC group, 2011-2013

Population base: Government controlled
Behaviour: Malignant

IARCCRT	All cases	DCO	DCO %
C00 Lip	12		
C01-C02 Tongue	42	2	4.8%
C03-C06 Mouth	24		
C07-C08 Salivary glands	24	3	12.5%
C09 Tonsil	13		
C10 Other Oropharynx	6		
C11 Nasopharynx	7		
C12-C13 Hypopharynx	3		
C14 Pharynx unspec.			
C15 Oesophagus	22	3	13.6%
C16 Stomach	267	19	7.1%
C17 Small intestine	14		
C18-C20 Colorectal	1122	69	6.1%
C21 Anus	12		
C22 Liver	157	57	36.3%
C23-C24 Gallbladder etc.	83	7	8.4%
C25 Pancreas	229	47	20.5%
C30-C31 Nose, sinuses etc.	9		
C32 Larynx	93	5	5.4%
C33-C34 Tr., Br., Lung	933	97	10.4%
C37-C38 Other Thoracic organs	13	2	15.4%
C40-C41 Bone	23	3	13.0%
C43 Melanoma of Skin	203	4	2.0%
C45 Mesothelioma	33	3	9.1%
C46 Kaposi sarcoma	7		
C47;C49 Connective, Soft tissue	73	4	5.5%
C50 Breast	1686	66	3.9%
C51 Vulva	27	1	3.7%
C52 Vagina	5		
C53 Cervix Uteri	105	2	1.9%
C54 Corpus Uteri	279	4	1.4%
C55 Uterus unspec.	12	5	41.7%
C56 Ovary	175	9	5.1%
C57 Other Female Genital	4	1	25.0%
C58 Placenta			
C60 Penis	19	1	5.3%
C61 Prostate	1478	91	6.2%
C62 Testis	110	1	0.9%
C63 Other male genital	1		
C64 Kidney	193	9	4.7%
C65 Renal Pelvis	7		
C66 Ureter	6	1	16.7%
C67 Bladder	460	12	2.6%
C68 Other Urinary organs	3	1	33.3%
C69 Eye	12	2	16.7%
C70-C72 Brain, & NS	150	27	18.0%
C73 Thyroid	684	2	0.3%
C74 Adrenal gland	4		
C75 Other Endocrine	1		
C81 Hodgkin disease	107	3	2.8%
C82-C85;C96 NHL	380	11	2.9%
C88 Immunoproliferative dis	3	2	66.7%
C90 Multiple Myeloma	129	17	13.2%
C91 Lymphoid Leukaemia	136	29	21.3%
C92-C94 Myeloid Leukaemia	101	19	18.8%
C95 Leukaemia unspec.	28	22	78.6%
MDS Myelodysplastic syndr	58	28	48.3%
MPD Myeloproliferative dis	31	7	22.6%
O&U Other & Unspecified	186	67	36.0%
Total	10004	765	7.6%

Record status:	Confirmed
Behaviour:	Malignant
Year:	2011-2013

IARCCRT	DCO	Non-DCO	Total	%DCO
C33-C34 Tr., Br., Lung	97	836	933	10%
C61 Prostate	91	1387	1478	6%
C18-C20 Colorectal	69	1053	1122	6%
O&U Other & Unspecified	67	119	186	36%
C50 Breast	66	1620	1686	4%
C22 Liver	57	100	157	36%
C25 Pancreas	47	182	229	21%
C91 Lymphoid Leukaemia	29	107	136	21%
MDS Myelodysplastic syndrome	28	30	58	48%
C70-C72 Brain, & NS	27	123	150	18%
C95 Leukaemia unspec.	22	6	28	79%
C92-C94 Myeloid Leukaemia	19	82	101	19%
C16 Stomach	19	248	267	7%
C90 Multiple Myeloma	17	112	129	13%
C67 Bladder	12	448	460	3%
C82-C85;C96 NHL	11	369	380	3%
C64 Kidney	9	184	193	5%
C56 Ovary	9	166	175	5%
C23-C24 Gallbladder etc.	7	76	83	8%
MPD Myeloproliferative disease	7	24	31	23%
C32 Larynx	5	88	93	5%
C55 Uterus unspec.	5	7	12	42%
C47;C49 Connective, Soft tissue	4	69	73	5%
C43 Melanoma of Skin	4	199	203	2%
C54 Corpus Uteri	4	275	279	1%
C40-C41 Bone	3	20	23	13%
C81 Hodgkin disease	3	104	107	3%
C45 Mesothelioma	3	30	33	9%
C07-C08 Salivary glands	3	21	24	13%
C15 Oesophagus	3	19	22	14%
C88 Immunoproliferative dis	2	1	3	67%
C53 Cervix Uteri	2	103	105	2%
C37-C38 Other Thoracic organs	2	11	13	15%
C01-C02 Tongue	2	40	42	5%
C73 Thyroid	2	682	684	0%
C69 Eye	2	10	12	17%
C68 Other Urinary organs	1	2	3	33%
C57 Other Female Genital	1	3	4	25%
C51 Vulva	1	26	27	4%
C62 Testis	1	109	110	1%
C66 Ureter	1	5	6	17%
C60 Penis	1	18	19	5%
C12-C13 Hypopharynx		3	3	
C63 Other male genital		1	1	
C17 Small intestine		14	14	
C52 Vagina		5	5	
C00 Lip		12	12	
C30-C31 Nose, sinuses etc.		9	9	
C10 Other Oropharynx		6	6	
C11 Nasopharynx		7	7	
C14 Pharynx unspec.				
C58 Placenta				
C46 Kaposi sarcoma		7	7	
C75 Other Endocrine		1	1	
C65 Renal Pelvis		7	7	
C03-C06 Mouth		24	24	
C21 Anus		12	12	
C74 Adrenal gland		4	4	
C09 Tonsil		13	13	
Total	765	9239	10004	8%

Main problems in collecting the data

- Incomplete Hospital Records.
- Incomplete Information Technology System in Government Hospitals.
- Inappropriate Storage of records in the hospitals (inaccessible or mislaid).
- Lack of Notification Law.

e) Changes in the cancer statistical form

The Cancer Registration Form designed in 2009 and slightly modified in 2010 was used during 2011-2016. The form is shown in Appendix I.

f) Computer database management

The changes in the computer programme **CanReg4** made in 2009 have remained stable with a few minor modifications. New fields were added (particularly on treatment data), other fields were modified. No fields were deleted.

The procedures of **electronic data uploading** from Excel files obtained from BOCOC are being followed as in the previous year. Importing of electronic data mainly involves the demographic data. Morphology data are not available and Topography data do not always conform to ICD-O-3. All such data uploaded in the Cancer Registry are entered as pending. They are checked in the usual manner by the Cancer Registrars before being confirmed.

Back-up procedures follow a rotation scheme of daily, weekly and monthly full back-ups using the CanReg4 back-up facility.

In 2016 we repeated the routine **quality checks** we introduced in previous years. These included IARC tools, DEP edits and the computer edits recommended in the SEER Summary Staging Manual. We have also used our own computer checks in the Health Monitoring Unit Data Warehouse.

Data analysis and reporting is done by the HMU statistician and the PI using various tools such as IBM DB2, Microsoft Access, Excel, SPSS, Word, Powerpoint etc.

g) Standardized tables and graphs

MECC Table 1. Revised Estimated Number of persons living in Cyprus in 2011-2013.

Age	2011			2012			2013		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
0-4	25022	23859	48881	25505	24248	49753	24911	23781	48692
5-9	23186	21811	44997	23428	22061	45489	23620	22244	45864
10-14	24683	23675	48358	23912	22647	46559	23108	21934	45042
15-19	31808	30383	62191	29989	28583	58572	28172	26679	54851
20-24	36471	35362	71833	36192	34904	71096	34474	32978	67452
25-29	36847	38312	75159	36973	38126	75099	36130	36516	72646
30-34	32916	36728	69644	33803	37403	71206	34113	36952	71065
35-39	28228	34008	62236	28384	33809	62193	28380	33234	61614
40-44	26656	31440	58096	27189	32207	59396	27216	32370	59586
45-49	27669	30219	57888	27283	30268	57551	26639	30050	56689
50-54	27767	28873	56640	28035	29398	57433	27924	29542	57466
55-59	24244	24689	48933	24679	25245	49924	25154	25889	51043
60-64	22952	23762	46714	23233	23986	47219	23141	23842	46983
65-69	16974	18187	35161	17811	19187	36998	18916	20328	39244
70-74	13985	15349	29334	14271	15709	29980	14373	15947	30320
75-79	9443	11740	21183	9932	12076	22008	10413	12493	22906
80-84	5930	8274	14204	6143	8438	14581	6390	8827	15217
85+	4212	6347	10559	4278	6543	10821	4464	6856	11320
Total	**418993**	**443018**	**862011**	**421040**	**444838**	**865878**	**417538**	**440462**	**858000**

Source: Statistical Service of Cyprus, Ministry of Finance. Revised on the basis of Census 2011.



MECC Table 2. Number of new cases of cancer by IARC group, and sex, 2012-2013

Population base: All, Including non-residents
Behaviour: Malignant

IARC group	2012						2013					
	Male		Female		Total		Male		Female		Total	
	Count	%	Count	%	Count	%	Count	%	Count	%	Count	%
C00 Lip	2	0.1%			**2**	0.1%	2	0.1%			**2**	0.1%
C01-C02 Tongue	6	0.3%	7	0.4%	**13**	0.4%	9	0.5%	7	0.5%	**16**	0.5%
C03-C06 Mouth	8	0.5%	3	0.2%	**11**	0.3%	6	0.3%	1	0.1%	**7**	0.2%
C07-C08 Salivary glands	7	0.4%	3	0.2%	**10**	0.3%	2	0.1%	2	0.1%	**4**	0.1%
C09 Tonsil	3	0.2%	1	0.1%	**4**	0.1%	3	0.2%	3	0.2%	**6**	0.2%
C10 Other Oropharynx	2	0.1%			**2**	0.1%	1	0.1%			**1**	0.0%
C11 Nasopharynx	2	0.1%	1	0.1%	**3**	0.1%	1	0.1%			**1**	0.0%
C12-C13 Hypopharynx	1	0.1%			**1**	0.0%	1	0.1%	1	0.1%	**2**	0.1%
C14 Pharynx unspec.												
C15 Oesophagus	5	0.3%	1	0.1%	**6**	0.2%	9	0.5%			**9**	0.3%
C16 Stomach	59	3.4%	35	2.2%	**94**	2.8%	46	2.6%	43	2.8%	**89**	2.7%
C17 Small intestine	4	0.2%			**4**	0.1%	3	0.2%	3	0.2%	**6**	0.2%
C18 Colon	175	10.0%	114	7.2%	**289**	8.7%	137	7.9%	113	7.3%	**250**	7.6%
C19-C20 Rectum	71	4.1%	34	2.1%	**105**	3.2%	64	3.7%	30	1.9%	**94**	2.9%
C21 Anus	1	0.1%	4	0.3%	**5**	0.2%			1	0.1%	**1**	0.0%
C22 Liver	40	2.3%	15	0.9%	**55**	1.7%	30	1.7%	22	1.4%	**52**	1.6%
C23-C24 Gallbladder etc.	14	0.8%	12	0.8%	**26**	0.8%	14	0.8%	13	0.8%	**27**	0.8%
C25 Pancreas	47	2.7%	32	2.0%	**79**	2.4%	42	2.4%	25	1.6%	**67**	2.0%
C30-C31 Nose, sinuses etc.	3	0.2%			**3**	0.1%	3	0.2%	1	0.1%	**4**	0.1%
C32 Larynx	36	2.1%	3	0.2%	**39**	1.2%	24	1.4%	2	0.1%	**26**	0.8%
C33-C34 Tr., Br., Lung	232	13.3%	63	4.0%	**295**	8.9%	253	14.5%	68	4.4%	**321**	9.7%
C37-C38 Other Thoracic organs	3	0.2%	3	0.2%	**6**	0.2%	2	0.1%	3	0.2%	**5**	0.2%
C40-C41 Bone	5	0.3%	2	0.1%	**7**	0.2%	3	0.2%	2	0.1%	**5**	0.2%
C43 Melanoma of Skin	32	1.8%	26	1.6%	**58**	1.7%	45	2.6%	34	2.2%	**79**	2.4%
C45 Mesothelioma	8	0.5%	5	0.3%	**13**	0.4%	6	0.3%	4	0.3%	**10**	0.3%
C46 Kaposi sarcoma	2	0.1%			**2**	0.1%	2	0.1%			**2**	0.1%
C47;C49 Connective, Soft tissue	13	0.7%	14	0.9%	**27**	0.8%	7	0.4%	6	0.4%	**13**	0.4%
C50 Breast	8	0.5%	542	34.2%	**550**	16.5%	10	0.6%	546	35.1%	**556**	16.9%
C51 Vulva			7	0.4%	**7**	0.2%			8	0.5%	**8**	0.2%
C52 Vagina			1	0.1%	**1**	0.0%						
C53 Cervix Uteri			38	2.4%	**38**	1.1%			40	2.6%	**40**	1.2%
C54 Corpus Uteri			94	5.9%	**94**	2.8%			94	6.0%	**94**	2.9%
C55 Uterus unspec.			4	0.3%	**4**	0.1%			4	0.3%	**4**	0.1%
C56 Ovary			41	2.6%	**41**	1.2%			66	4.2%	**66**	2.0%
C57 Other Female Genital			4	0.3%	**4**	0.1%						
C58 Placenta												
C60 Penis	6	0.3%			**6**	0.2%	7	0.4%			**7**	0.2%
C61 Prostate	489	28.0%			**489**	14.7%	494	28.3%			**494**	15.0%
C62 Testis	42	2.4%			**42**	1.3%	33	1.8%			**33**	1.0%
C63 Other Male genital	1	0.1%			**1**	0.0%						
C64 Kidney	42	2.4%	30	1.9%	**72**	2.2%	40	2.3%	21	1.4%	**61**	1.9%
C65 Renal Pelvis	1	0.1%			**1**	0.0%	4	0.2%	1	0.1%	**5**	0.2%
C66 Ureter	2	0.1%			**2**	0.1%	1	0.1%	1	0.1%	**2**	0.1%
C67 Bladder	113	6.5%	22	1.4%	**135**	4.1%	147	8.4%	26	1.7%	**173**	5.2%
C68 Other Urinary organs	1	0.1%			**1**	0.0%	1	0.1%			**1**	0.0%
C69 Eye	1	0.1%	1	0.1%	**2**	0.1%	2	0.1%	2	0.1%	**4**	0.1%
C70-C72 Brain, & NS	29	1.7%	30	1.9%	**59**	1.8%	30	1.7%	15	1.0%	**45**	1.4%
C73 Thyroid	36	2.1%	200	12.6%	**236**	7.1%	49	2.8%	168	10.8%	**217**	6.6%
C74 Adrenal gland			1	0.1%	**1**	0.0%	1	0.1%			**1**	0.0%
C75 Other Endocrine							1	0.1%			**1**	0.0%
C81 Hodgkin disease	9	0.5%	19	1.2%	**28**	0.8%	24	1.4%	24	1.5%	**48**	1.5%
C82-C85;C96 NHL	63	3.6%	57	3.6%	**120**	3.6%	70	4.0%	66	4.2%	**136**	4.1%
C88 Immunoproliferative dis	1	0.1%			**1**	0.0%			2	0.1%	**2**	0.1%
C90 Multiple Myeloma	19	1.1%	25	1.6%	**44**	1.3%	24	1.4%	20	1.3%	**44**	1.3%
C91 Lymphoid Leukaemia	22	1.3%	23	1.5%	**45**	1.4%	27	1.5%	16	1.0%	**43**	1.3%
C92-C94 Myeloid Leukaemia	19	1.1%	18	1.1%	**37**	1.1%	17	1.0%	13	0.8%	**30**	0.9%
C95 Leukaemia unspec.	4	0.2%	6	0.4%	**10**	0.3%	7	0.4%	2	0.1%	**9**	0.3%
MDS Myelodysplastic syndr	12	0.7%	7	0.4%	**19**	0.6%	9	0.5%	5	0.3%	**14**	0.4%
MPD Myeloproliferative dis	9	0.5%	6	0.4%	**15**	0.5%			1	0.1%	**1**	0.0%
O&U Other & Unspecified	34	1.9%	31	2.0%	**65**	2.0%	30	1.7%	29	1.9%	**59**	1.8%
Total	**1744**	**100%**	**1585**	**100%**	**3329**	**100%**	**1743**	**100%**	**1554**	**100%**	**3297**	**100%**

MECC Table 3. Ten most common male cancers in 2013

IARC Group	Count	%
C61 Prostate	494	28.3%
C33-C34 Tr., Br., Lung	253	14.5%
C18-C20 Colorectal	201	11.5%
C67 Bladder	147	8.4%
C82-C85;C96 NHL	70	4.0%
C73 Thyroid	49	2.8%
C16 Stomach	46	2.6%
C43 Melanoma Skin	45	2.6%
C25 Pancreas	42	2.4%
C64 Kidney	40	2.3%
All others	356	20.4%
Total	1743	100.0%



MECC Table 4. Ten most common female cancers in 2013

IARC Group	Count	%
C50 Breast	546	35.1%
C73 Thyroid	168	10.8%
C18-C20 Colorectal	143	9.2%
C54 Corpus Uteri	94	6.0%
C33-C34 Tr., Br., Lung	68	4.4%
C82-C85;C96 NHL	66	4.2%
C56 Ovary	43	2.8%
C16 Stomach	40	2.6%
C53 Cervix Uteri	34	2.2%
C43 Melanoma Skin	29	1.9%
All others	323	20.8%
Total	1554	100.0%



MECC Table 5. World Age Standardized Incidence rates by year, by sex, by IARC group.

IARC group	2010		2011		2012		2013	
	M	F	M	F	M	F	M	F
C00 Lip	0.6	0.3	0.9	0.2	0.3		0.2	
C01-C02 Tongue	1.1	0.7	1.6	0.3	1.0	1.0	1.5	1.1
C03-C06 Mouth	1.3	0.5	0.2	0.5	1.3	0.4	1.0	0.2
C07-C08 Salivary glands	0.5		0.7	0.7	0.9	0.3	0.2	0.3
C09 Tonsil	0.4	0.3	0.4	0.2	0.4	0.2	0.5	0.5
C10 Other Oropharynx	0.1		0.6		0.4		0.2	
C11 Nasopharynx	0.4	0.4	0.6		0.3	0.2	0.2	
C12-C13 Hypopharynx		0.1			0.2		0.2	0.2
C14 Pharynx unspec.	0.2							
C15 Oesophagus	1.8	0.2	0.5	0.7	0.8	0.2	1.3	
C16 Stomach	6.5	5.1	6.6	5.3	9.1	3.3	6.9	4.5
C17 Small intestine	0.9	0.6	0.4	0.3	0.6		0.3	0.4
C18-C20 Colorectal	31.3	21.2	33.2	21.3	33.8	17.8	26.3	17.7
C21 Anus	0.3	0.9		0.8	0.2	0.6		
C22 Liver	3.8	1.4	4.3	2.0	5.6	1.7	4.0	2.5
C23-C24 Gallbladder etc.	1.6	1.2	1.7	2.1	1.7	1.4	1.9	1.8
C25 Pancreas	6.9	3.3	7.4	4.5	6.8	4.1	5.6	2.8
C30-C31 Nose, sinuses etc.	0.4		0.1	0.1	0.5		0.4	0.2
C32 Larynx	4.4	0.1	4.1	0.2	5.4	0.6	3.6	0.3
C33-C34 Tr., Br., Lung	32.6	8.2	35.3	9.7	33.1	8.0	36.0	9.5
C37-C38 Other Thoracic organs		0.3	0.4		0.4	0.4	0.4	0.7
C40-C41 Bone	1.6	1.9	1.1	1.4	1.1	0.5	0.5	0.6
C43 Melanoma of Skin	5.7	3.7	5.4	4.9	5.2	4.0	5.9	5.1
C45 Mesothelioma	1.1	0.3	1.3	0.1	1.1	0.7	0.8	0.5
C46 Kaposi sarcoma	0.4	0.1	0.2	0.2	0.3		0.3	
C47;C49 Connective, Soft tissue	2.1	2.1	1.9	3.2	2.3	1.8	0.9	1.0
C50 Breast	0.5	80.3	0.8	85.8	1.2	77.6	1.3	80.0
C51 Vulva		1.5		1.2		0.9		1.0
C52 Vagina				0.5		0.1		
C53 Cervix Uteri		6.1		4.3		6.5		6.4
C54 Corpus Uteri		14.2		12.6		13.4		12.9
C55 Uterus unspec.		0.4		0.6		0.5		0.5
C56 Ovary		7.7		9.9		5.8		9.6
C57 Other Female Genital						0.6		
C58 Placenta								
C60 Penis	1.4		0.9		0.9		1.2	
C61 Prostate	64.8		69.9		67.4		66.7	
C62 Testis	4.7		7.7		8.3		6.8	
C63 Other male genital					0.2			
C64 Kidney	7.5	2.9	6.0	3.8	6.3	4.6	5.5	2.9
C65 Renal Pelvis	0.3	0.2		0.2	0.2		0.6	0.1
C66 Ureter	0.2		0.2	0.1	0.2		0.2	0.1
C67 Bladder	17.7	3.1	18.0	2.6	16.2	2.2	19.8	2.6
C68 Other Urinary organs	0.3		0.1		0.1			
C69 Eye	0.5	0.1	0.7	0.5	0.2	0.2	0.3	0.3
C70-C72 Brain, & NS	5.3	3.1	4.0	3.5	5.2	4.4	5.2	2.1
C73 Thyroid	7.9	29.5	9.6	33.7	7.1	34.4	9.6	29.9
C74 Adrenal gland	0.7		0.2	0.2		0.2	0.2	
C75 Other Endocrine							0.2	
C81 Hodgkin disease	4.6	3.2	2.4	3.2	2.3	4.2	5.0	4.7
C82-C85;C96 NHL	10.5	10.8	9.0	8.1	10.0	8.0	11.7	8.9
C88 Immunoproliferative dis					0.2			0.1
C90 Multiple Myeloma	3.1	2.9	3.2	2.4	2.7	2.3	2.9	2.5
C91 Lymphoid Leukaemia	5.6	2.5	6.3	4.0	4.2	3.3	4.9	2.7
C92-C94 Myeloid Leukaemia	3.7	2.6	2.4	3.1	3.2	2.1	2.7	1.4
C95 Leukaemia unspec.	0.9	0.4	0.5	0.4	0.6	0.6	0.8	0.2
MDS Myelodysplastic syndr	3.5	0.5	2.5	0.3	1.8	0.6	1.0	0.5
MPD Myeloproliferative dis	1.0	1.4	1.1	0.9	1.5	0.9		0.1
O&U Other & Unspecified	6.1	2.6	4.8	2.7	4.5	3.8	3.6	3.0
All but NMS	256.5	228.7	259.1	242.9	257.4	224.2	249.0	221.9

MECC Table 6. Age Specific Incidence Rates of Prostate cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C61 Prostate cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		
25-29		
30-34		
35-39		
40-44	1.9	
45-49	15.0	
50-54	54.1	
55-59	125.0	
60-64	297.6	
65-69	499.6	
70-74	739.1	
75-79	843.8	
80-84	711.2	
85+	748.5	
Crude IR	**109.9**	
WASR	**66.1**	



MECC Table 7. Age Specific Incidence Rates of Bladder cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C67 Bladder cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19		0.6
20-24	0.5	
25-29	0.5	0.5
30-34	2.2	
35-39	6.2	
40-44	6.5	2.2
45-49	10.0	0.6
50-54	22.8	6.1
55-59	34.2	4.9
60-64	78.6	6.8
65-69	122.9	16.1
70-74	177.7	18.4
75-79	190.8	38.4
80-84	253.6	46.6
85+	173.0	59.6
Crude IR	**30.1**	**5.4**
WASR	**18.5**	**2.8**



MECC Table 8. Age Specific Incidence Rates of Trachea, Bronchus & Lung cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C33-C34 Tr., Br., Lung cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19	0.5	0.6
20-24	0.5	0.5
25-29		1.4
30-34	3.2	1.9
35-39	2.4	3.6
40-44	10.7	5.5
45-49	15.3	9.0
50-54	47.2	16.8
55-59	85.0	26.0
60-64	153.8	31.7
65-69	243.5	57.6
70-74	323.0	66.3
75-79	316.1	69.5
80-84	322.4	74.6
85+	314.4	55.7
Crude IR	**54.2**	**14.7**
WASR	**34.0**	**9.0**



MECC Table 9. Age Specific Incidence Rates of Colon cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C18 Colon cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19		0.6
20-24	0.5	0.5
25-29	2.4	1.4
30-34	2.7	2.5
35-39	3.7	3.1
40-44	7.0	15.5
45-49	18.5	20.6
50-54	25.1	27.4
55-59	51.4	37.6
60-64	77.7	48.7
65-69	128.6	69.8
70-74	184.5	107.3
75-79	223.2	119.1
80-84	273.9	214.8
85+	354.5	191.4
Crude IR	**35.2**	**26.4**
WASR	**21.5**	**15.0**



MECC Table 10. Age Specific Incidence Rates of Rectal cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C19-C20 Rectum cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19	0.5	
20-24		0.5
25-29		
30-34	0.5	0.5
35-39	3.0	1.0
40-44	1.3	2.7
45-49	6.1	3.9
50-54	16.8	7.7
55-59	25.8	10.9
60-64	38.9	19.8
65-69	50.7	25.8
70-74	82.1	36.8
75-79	104.3	33.0
80-84	88.5	45.2
85+	100.9	52.7
Crude IR	**14.9**	**7.7**
WASR	**9.3**	**4.5**



MECC Table 11. Age Specific Incidence Rates of Non-Hodgkin Lymphoma, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C82-C85;C96 NHL

Age group	Male	Female
0-4	0.7	
5-9	1.5	
10-14	0.7	0.7
15-19	1.6	1.7
20-24	1.9	2.0
25-29	2.8	4.6
30-34	5.4	4.4
35-39	9.7	6.2
40-44	10.1	4.9
45-49	10.4	9.6
50-54	19.8	17.5
55-59	26.4	24.7
60-64	37.2	31.8
65-69	52.6	35.4
70-74	52.1	60.9
75-79	64.5	66.8
80-84	82.6	74.8
85+	48.3	55.9
Crude IR	**15.0**	**14.4**
WASR	**10.4**	**9.0**



MECC Table 12. Age Specific Incidence Rates of Breast cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C50 Breast cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		1.0
25-29		4.1
30-34		26.5
35-39	0.6	69.3
40-44		128.7
45-49	0.6	196.5
50-54	1.9	219.7
55-59	4.2	241.2
60-64	4.5	296.6
65-69	4.0	319.9
70-74	6.2	302.0
75-79	12.5	285.2
80-84	2.8	297.1
85+	8.0	311.6
Crude IR	**1.5**	**116.0**
WASR	**0.9**	**79.7**



MECC Table 13. Age Specific Incidence Rates of Corpus Uteri cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C54 Corpus Uteri cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		0.5
25-29		
30-34		1.9
35-39		3.1
40-44		7.7
45-49		10.7
50-54		40.9
55-59		49.4
60-64		64.3
65-69		81.9
70-74		81.0
75-79		75.4
80-84		83.0
85+		26.6
Crude IR		**20.8**
WASR		**13.4**



MECC Table 14. Age Specific Incidence Rates of Stomach cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C16 Stomach cancer

Age group	Male	Female
0-4		
5-9	0.7	
10-14		
15-19		
20-24		
25-29	1.0	1.8
30-34	0.5	
35-39	3.1	1.0
40-44	2.5	0.5
45-49	4.3	7.3
50-54	14.4	8.4
55-59	19.6	13.0
60-64	37.5	16.9
65-69	41.0	15.7
70-74	58.7	33.6
75-79	70.4	54.8
80-84	57.4	86.8
85+	97.3	63.5
Crude IR	**12.0**	**8.8**
WASR	**7.7**	**4.7**



MECC Table 15. Age Specific Incidence Rates of Thyroid cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C73 Thyroid cancer

Age group	Male	Female
0-4		
5-9		0.8
10-14	0.7	3.5
15-19	5.3	10.1
20-24	5.7	21.0
25-29	9.5	33.0
30-34	9.1	31.7
35-39	14.5	57.9
40-44	16.4	60.7
45-49	19.5	65.5
50-54	15.4	75.6
55-59	13.2	68.6
60-64	15.9	57.8
65-69	10.9	55.3
70-74	16.1	30.1
75-79	10.7	15.8
80-84	2.8	8.2
85+	4.0	7.9
Crude IR	**9.7**	**37.1**
WASR	**8.0**	**29.9**



MECC Table 16. Age Specific Incidence Rates of Cervix uteri cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C53 Cervix Uteri cancer

Age group	Male	Female
0-4		
5-9		
10-14		
15-19		
20-24		0.5
25-29		4.6
30-34		5.8
35-39		14.3
40-44		17.9
45-49		17.9
50-54		9.5
55-59		10.9
60-64		8.1
65-69		7.4
70-74		7.8
75-79		12.9
80-84		14.4
85+		2.6
Crude IR		**7.4**
WASR		**5.6**



MECC Table 17. Age Specific Incidence Rates of Liver cancer, 2008-2013

CyCR: 2008-2013, Age Specific, Crude and WASR Incidence Rates
C22 Liver cancer

Age group	Male	Female
0-4		
5-9		0.8
10-14		
15-19		
20-24	0.9	
25-29	0.5	
30-34		0.5
35-39		0.5
40-44	1.3	0.5
45-49	1.2	1.7
50-54	6.2	3.0
55-59	9.0	2.0
60-64	17.4	5.1
65-69	24.7	12.0
70-74	39.6	15.6
75-79	67.9	17.2
80-84	36.9	22.6
85+	96.3	57.9
Crude IR	**7.5**	**3.6**
WASR	**4.5**	**2.0**



Childhood Cancer

MECC Table 18. Female childhood cancers, 0-14 yrs, 2011-2013

Behaviour: Malignant
Population base: Government controlled areas
Sex: Female

MECC ICD-10 categories	2011				2012				2013				Total
	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	
Lymphoid Leukaemia (C91)	1	1		2	1	1		2	2			2	6
Bone (C40-C41)		1		1							1	1	2
Thyroid (C73)			2	2									2
Brain, & NS (C70-C72)	1			1		1		1					2
Hodgkin disease (C81)			1	1			1	1					2
Connective, Soft tissue (C47;C49)			1	1									1
Kidney (C64)	1			1									1
Myeloid Leukaemia (C92-C94)	1			1									1
Total	4	2	4	10	1	2	1	4	2		1	3	17



MECC Table 19. Male childhood cancers, 0-14 yrs, 2011-2013

Behaviour: Malignant
Population base: Government controlled areas
Sex: Male

MECC ICD-10 categories	2011				2012				2013				Total
	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	0-4	5-9	10-14	Total	
Lymphoid Leukaemia (C91)	4		1	5	2	2		4		2	1	3	12
Brain, & NS (C70-C72)	1			1			1	1			1	1	3
Non-Hodgkin Lymphoma (C82-C85;C96)									1		1	2	2
Bone (C40-C41)			1	1			1	1					2
Hodgkin disease (C81)						1		1					1
Stomach (C16)						1		1					1
Eye (C69)	1			1									1
Thyroid (C73)											1	1	1
Connective, Soft tissue (C47;C49)					1			1					1
Myeloid Leukaemia (C92-C94)						1		1					1
Kidney (C64)			1	1									1
Total	6		3	9	3	5	2	10	1	2	4	8	26



h) Notifiability of cancer in the country

One of the aims of the National Cancer Strategy is the introduction of legislation on Notifiability of Cancer. A draft law enabling the Health Monitoring Unit to collect health data including confidential cancer data was submitted to the Health Committee of the House of Representatives in 2013 for preliminary examination. The representative of the Commissioner for Personal Data Protection and a number of the House Representatives felt the draft needed further modifications in order to be in line with the personal data protection law.

Although the above draft law is a general instrument for collection of health data, it will, if passed, allow the government to issue regulations on specific health information topics, including cancer. Such regulations will specify the details of data items to be collected. The draft was prepared taking into account the recommendations of MECC Standard Operating Procedures. Comments by stakeholders were received and they were taken into account.

i) Linking up with death certificates

The quality of **death certification** and codification has improved since 2004. Coding is done by Health Monitoring Unit, on multiple and underlying causes of death. Manual and automated coding was done using the MMDS (SUPERMICAR, MICAR and ACME/TRANSAX) software since 2004. From 2012 onwards, we have adopted the IRIS automated coding software. About 85% of deaths are coded automatically. The rest need to be coded manually by interaction with IRIS for the application of the ICD-10 rules for mortality. ICD-10 updates are applied for the corresponding year according to the latest version of ACME (now IRIS). Querying of death certificates is done on a regular basis by telephone and/or fax. The coverage of deaths in Cypriot residents, including those dying abroad, has improved significantly in recent years.

It is now **possible to link** the Death Registry to the Cancer Registry by using the patients' national ID number. In a small proportion of deaths this is not possible because of the absence of a national ID in the death register or the cancer register or because of errors in recording the ID. The great majority of cases can, however, be linked. In 2016 we continued the linkage procedure introduced in 2009. This allows the uploading of a significant number of Death Certificate Notified (DCN) cancers. In Cyprus there are more than 1000 annual deaths with cancer recorded as the underlying cause of death. Some more certificates have cancer mentioned in the multiple causes. All such death certificates are imported into CanReg4 as pending cases of cancer. They go through the usual checks for duplicates and they are either confirmed as new cases or deleted. Before deletion, any updates on followup dates or other data items are done in CanReg4. A substantial number of these cases remain as Death Certificate Only (DCO) cases because of difficulties with follow-back procedures.

This linkage has **improved the completeness** of cancer registration in Cyprus. However, the percentage of DCO cases is still relatively high. At present, the percentage of DCO cases for the period 2011-2013 is around 7 % compared to about 10% in 2004.

Linkage has also made it possible to improve the completeness and accuracy of follow-up data. We are now able to use our followup data for the calculation of cancer survival. Cyprus has participated in the CONCORD2 project which resulted in the publication of "*Global surveillance of cancer survival 1995–2009*" in 2014. At present, we are preparing our data for submission to the CONCORD3 project.

Follow-back of the DCO cases is not easy. It requires a lot of active casefinding activity. It often needs contacting general practitioners and private physicians. We have estimated that about 50% of these cases are certified by non hospital doctors. Record keeping in doctors' offices is not always complete. The registrars have difficulty in getting the cooperation of private physicians. Existing staff cannot cover all of this new workload.

j) Local activities

We carried on with **Cancer cluster** investigations as in previous years. The number of new claims for investigation has dropped significantly. Some 'statistical clusters', for specific types of cancer, were identified, but they involved small numbers of cases. They could not lead to concrete conclusions. No 'meaningful clusters' have been found. As a result of this activity, the problem of numerous community cancer concerns, that had been raised by local authorities or members of parliament, during the past ten years, appears to be coming to a conclusion. The relevant reports were prepared by the Cancer Registry and sent to community leaders, members of parliament and other stakeholders. The recent improvements in the quality and completeness of cancer registration were well documented and publicized. This seems to have made it possible to provide adequate reassurance to people.

The **Registry Data is requested** and broadly used by many professionals for presentations, reporting and use in scientific work. There is a growing volume for such requests and on many occasions they are published in the media.

Clinical coding in public hospitals has made significant progress in 2014 and 2015. The number of coders and their training and experience have improved. However it is not yet possible to cover all cases. Clinical coding is under the direction of the Health Monitoring Unit. Some degree of priority is given to coding oncology cases. The gradual increase in coverage and quality of codification of diagnoses and medical procedures is expected to improve the possibility of exporting electronic files from the public hospitals to the cancer registry.

Current casefinding procedures regarding the **collection of microscopy reports** have improved from purely manual procedures to a mixture of manual and electronic means. At least one pathology laboratory has cooperated in providing histology reports and listings in electronic format instead of paper reports. The selection of histology reports with reportable cancers is now done by the cancer registrars instead of the histology clerks. This has improved the completeness of casefinding. The previous methodology resulted in missing a number of reportable cases of cancer.

Since 2010 the **speed of data entry** has improved significantly. The most significant factor in speeding up data entry has been the hard, voluntary work of the registry staff. It has also been improved as a result of importing a large volume of demographic and some tumour data in electronic form. Improvements in the organization of the work of casefinding and abstraction have also helped speed up data entry. Electronic lists of cases have been used instead of paper based lists.

It is noteworthy that this increased speed in data entry has been achieved, in parallel with the recent **increase in workload.** More work is needed due to the new **treatment and follow-up data** items and the increased annual **Number of new cases** of cancer.

Data entry for 2013 was completed at the time of writing this report. We hope that we shall finish data entry for 2014 in early 2017.

k) Problems

Medical Records in some facilities remain incomplete and some are difficult to locate. However the implementation of an Integrated Government Hospitals Health Information System is making progress. This is expected to facilitate the abstracting of cases from state hospitals.

Although linkage with the Causes of Death Register and the Civil Death Register has been achieved, the problem of incomplete registration in the years before 2004 and low quality certification continue to be major problems.

There is a need to review the staffing **needs** of the Cancer Registry. Lack of sufficient staff causes delays in registration.

Doctors' cooperation needs to be further strengthened in order to provide more accurate information on cancer cases. Without legislation to make cancer a notifiable disease the problem will persist.

Treatment data for 2008 onwards are collected electronically from BOCOC and public hospitals only. Chemotherapy, hormone therapy, immunotherapy and other therapy are collected from BOCOC pharmacy. Radiotherapy was, until recently, collected electronically from BOCOC,s hospital information system. During the past year BOCOC has encountered certain technical problems in providing radiotherapy data and these are collected manually by the registrars.

Cancer is **not yet a notifiable disease.** However, appropriate legislation is in the process of being introduced.

APPENDIX I. CyCR Cancer Registration Form

ΑΡΧΕΙΟ ΚΑΡΚΙΝΟΥ ΚΥΠΡΟΥ - ΜΟΝΑΔΑ ΠΑΡΑΚΟΛΟΥΘΗΣΗΣ ΥΓΕΙΑΣ
ΕΝΤΥΠΟ ΚΑΤΑΓΡΑΦΗΣ ΔΕΔΟΜΕΝΩΝ - Εμπιστευτικό Έγγραφο του Υπουργείου Υγείας

PATIENT

NATIONAL ID: | BOCOC: | Regi No:

FIRST NAME | SURNAME | FATHER | Sex:

Sex: 1 Male, 2 Female, 3 Herma., 9 Unknown

Birth Date: | Ethnicity:

Ethnicity: 1 Greek, 2 Turk, 3 Maronite, 4 Armenian, 5 Latin, 7 Other (Non-EU), 8 European Union, 9 Unknown

District of Birth: | BirthP: | BirthP Town:

ADDRESS AND SOCIOECONOMIC

STREET No TEXT | POST C | Residential status:

Residential status: 1 Cyprus, 2 CY - Turkish control, 3 British Bases, 4 Other EU countries, 8 Other non-EU, 9 Unknown

DISTR-TOWN-QUARTER

Resi District: | Resi: | Resi Town:

Strt: | Strt Town: | Strt Odos:

Smoking history: | Marital status: | TELEPHONES

Smoking history: 0 Never smoked, 1 Current smoker, 2 Former smoker, 9 Unknown sm. hist.

Marital status: 1 Single, nev. mar., 2 Married, 3 Separated, 4 Divorced, 5 Widowed, 9 Unknown

Occupation Category: | Occu: | Occupation:

TUMOR

DATE ADMISSION: | MPTot: | MPSeq:

Incidence date | AGE | SeqNo: | PRIMARY SITE TEXT | Behavior:

Behavior: 2 In situ, 3 Malignant

Topography: | Icd10:

MORPHOLOGY TEXT | ICDO3 | Basis of Diagnosis

Basis of Diagnosis: 0 Death certificate only, 1 Clinical only, 2 Clin.Invest. (incl. X-ray, US etc.), 3 Exploratory surgery/autopsy, 4 Specific biochem and/or Immun. test, 5 Cytology or hematology, 6 Histology of metastases, 7 Histology of primary, 8 Autopsy with conc. or prev. histology, 9 Unknown

Histology code

SEER SUMMARY STAGE TEXT | ICCC:

Laterality: | SEER Summary Stage: | Grade / Diff:

Laterality: 0 Not a paired site, 1 Right, 2 Left, 3 Unilateral NOS, 4 Bilateral, 9 Unknown / midline

SEER Summary Stage: 0 In situ, 1 Localized (Stage I for lymphomas), 2 Regional by Direct Extension, 3 Regional by Lymph Nodes, 4 Regional by both DE and LNs, 5 Regional NOS (Stage II for lymphomas), 7 Distant (Stage III or IV for lymphomas), 9 Unknown, undetermined

Grade / Diff: 1 Stage I; well differentiated, 2 Stage II; moderately differentiated, 3 Stage III; poorly differentiated, 4 Stage IV; undifferentiated, anaplastic, 5 T-cell; T-precursor, 6 B-cell; Pre-B; B-precursor, 7 Null cell; Non T-non B, 8 NK cell, 9 Unknown/not stated/non applicable

Printed: 25/06/2010 1 / 2

BOCOC:

SOURCES

Regi No:

NOTIFIER-CERTIFIER

Notified by

PatNo 1:

Contact Phys:

PatNo 4:

Hospital-Clinic

PatNo 3:

HISTOPATH1

HISTOPATH1

HISTOPATH1

Histologist 1:

Histologist 2:

Histologist 3:

Place of Diagnosis

PatNo 1:

Hospital From:

PatNo 2:

Hospital To

PatNo 3:

FOLLOWUP

Vital status:

0 Alive
1 Dead

DateLC:

UCOD:

0 Still alive
1 Died of cancer
2 Died of non-cancer
9 Died of unknown cause

TREATMENT

0 Treatment NOT GIVEN
1 Treatment GIVEN
7 Patient REFUSED
8 RECOMMENDED, Unknown if Received
9 UNKNOWN

Date First Cancer Treatment

Cancer Surgery given?

Date of Cancer Surgery

Radiotherapy given?

Date of Radiotherapy

Chemotherapy given?

Date of Chemotherapy

Hormone therapy given?

Date of Hormone therapy

Immunotherapy given?

Date of Immunotherapy

Other treatment given?

Date of Other treatment

Notes:

2 / 2

Printed: 25/06/2010

APPENDIX II. CanReg4 Frequencies 1998-2015

Number of cases by year by Record status / Sex

Frequencies by Year CanReg4 26/08/2016

Number of cases by year by Record status / Sex

Pending

	Unknown	Male	Female	Total
1998	0	0	0	0
1999	0	0	0	0
2000	0	0	0	0
2001	0	0	0	0
2002	0	0	0	0
2003	0	0	0	0
2004	0	1	0	1
2005	0	0	0	0
2006	0	0	0	0
2007	0	0	2	2
2008	0	4	2	6
2009	0	5	4	9
2010	0	1	3	4
2011	0	3	6	9
2012	0	3	2	5
2013	0	13	11	24
2014	0	1467	1345	2812
2015	0	987	1128	2115
	0	2484	2503	4987

Confirmed

	Unknown	Male	Female	Total
1998	0	811	864	1675
1999	0	826	846	1672
2000	0	942	858	1800
2001	0	1000	963	1963
2002	0	1097	1029	2126
2003	0	1136	1106	2242
2004	0	1303	1180	2483
2005	0	1326	1229	2555
2006	0	1411	1260	2671
2007	0	1503	1500	3003
2008	0	1641	1572	3213
2009	0	1689	1528	3217
2010	0	1722	1631	3353
2011	0	1758	1724	3482
2012	0	1775	1647	3422
2013	0	1785	1639	3424
2014	0	50	58	108
2015	0	0	0	0
	0	21775	20634	42409

Number of cases by year by Basis of Diagnosis

Frequencies by Year CanReg4 26/08/2016

Number of cases by year by Basis

		1998	1999	2000	2001	2002	2003	2004	2005	2006	
1:	Death Certif: 0:	61	46	51	146	165	154	239	251	239	...
2:	Clinical Only: 1:	9	5	6	6	14	8	10	8	3	...
3:	Clinical Inves: 2:	24	36	35	29	51	24	24	23	31	...
4:	Surgery/Autp: 3:	9	6	3	0	1	0	0	0	1	...
5:	Bioc/ImmTest: 4:	4	2	6	0	1	0	0	0	0	...
6:	Cytol/Hemat: 5:	96	95	92	164	152	162	165	90	115	...
7:	Histol-Meta: 6:	17	25	62	68	83	84	86	101	86	...
8:	Histol-Prim: 7:	1428	1450	1530	1536	1636	1787	1946	2064	2177	...
9:	Autop+Histol: 8:	0	0	0	0	0	0	0	0	0	...
10:	Unknown: 9:	27	7	15	14	23	23	13	18	19	...
	Errors:	0	0	0	0	0	0	0	0	0	...
	Missing:	0	0	0	0	0	0	0	0	0	...

		2007	2008	2009	2010	2011	2012	2013	2014	2015		
1:	Death Certif: 0:	287	263	222	278	280	244	241	0	0	:	3167
2:	Clinical Only: 1:	2	3	2	1	1	1	3	0	0	:	82
3:	Clinical Inves: 2:	32	27	26	17	13	18	14	0	0	:	424
4:	Surgery/Autp: 3:	0	1	0	0	0	0	0	0	0	:	21
5:	Bioc/ImmTest: 4:	0	0	0	0	0	0	0	0	0	:	13
6:	Cytol/Hemat: 5:	102	77	101	81	78	72	59	0	0	:	1701
7:	Histol-Meta: 6:	115	91	84	90	80	98	94	2	0	:	1266
8:	Histol-Prim: 7:	2459	2747	2776	2874	3024	2978	3002	106	0	:	35520
9:	Autop+Histol: 8:	0	1	0	0	0	0	0	0	0	:	1
10:	Unknown: 9:	6	3	6	12	6	11	11	0	0	:	214
	Errors:	0	0	0	0	0	0	0	0	0	:	0
	Missing:	0	0	0	0	0	0	0	0	0	:	0

42409

Number of cases by year by Residential Status

Frequencies by Year CanReg4 26/08/2016

Number of cases by year by ReStat

		1998	1999	2000	2001	2002	2003	2004	2005	2006	
1:	CY GC: 1:	1656	1661	1793	1950	2122	2237	2469	2503	2521	...
2:	Occup: 2:	3	5	6	7	1	3	4	37	86	...
3:	Brit B: 3:	0	1	0	0	0	1	0	1	0	...
4:	EU: 4:	0	0	0	0	2	1	0	2	15	...
5:	Other: 8:	0	0	0	0	0	0	7	12	19	...
6:	Unkn: 9:	16	5	1	6	1	0	3	0	30	...
	Errors:	0	0	0	0	0	0	0	0	0	...
	Missing:	0	0	0	0	0	0	0	0	0	...

		2007	2008	2009	2010	2011	2012	2013	2014	2015		
1:	CY GC: 1:	2858	3044	3035	3200	3369	3305	3368	108	0	:	41199
2:	Occup: 2:	96	130	138	112	69	89	42	0	0	:	828
3:	Brit B: 3:	0	1	1	0	0	0	0	0	0	:	5
4:	EU: 4:	21	10	7	6	2	5	4	0	0	:	75
5:	Other: 8:	6	5	1	7	4	2	2	0	0	:	65
6:	Unkn: 9:	22	23	35	28	38	21	8	0	0	:	237
	Errors:	0	0	0	0	0	0	0	0	0	:	0
	Missing:	0	0	0	0	0	0	0	0	0	:	0

42409

Number of cases by year by Ethnicity

Frequencies by Year CanReg4 26/08/2016

Number of cases by year by Ethnic

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Greek: 1:	1553	1555	1659	1802	1922	2043	2232	2216	2192	...
2: Turkish: 2:	8	5	4	3	3	1	1	30	84	...
3: Maronite: 3:	1	4	2	1	4	2	4	5	1	...
4: Armenian: 4:	11	10	8	8	15	17	11	11	6	...
5: Latin: 5:	0	1	0	0	0	0	0	1	0	...
6: Other: 6:	28	26	26	45	56	45	60	70	26	...
7: Non-EU: 7:	56	53	62	64	64	80	95	113	67	...
8: EU: 8:	15	17	33	28	45	47	58	100	227	...
9: Unknown: 9:	3	1	6	12	17	7	22	9	68	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	0	0	0	0	0	0	0	0	0	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Greek: 1:	2490	2624	2616	2711	2878	2849	2872	94	0	:	36308
2: Turkish: 2:	90	123	130	103	63	85	40	0	0	:	773
3: Maronite: 3:	7	2	6	7	8	4	6	0	0	:	64
4: Armenian: 4:	12	11	6	8	6	12	17	1	0	:	170
5: Latin: 5:	2	0	1	1	0	0	0	0	0	:	6
6: Other: 6:	6	1	0	0	1	1	0	0	0	:	391
7: Non-EU: 7:	81	75	86	91	81	66	52	1	0	:	1187
8: EU: 8:	272	295	278	331	278	266	296	6	0	:	2592
9: Unknown: 9:	43	82	94	101	167	139	141	6	0	:	918
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	0	0	0	0	0	0	0	0	0	:	0

											42409

Number of cases by year by Sex

Frequencies by Year CanReg4 26/08/2016

Number of cases by year by Sex

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Male: 1:	811	826	942	1000	1097	1136	1303	1326	1411	...
2: Female: 2:	864	846	858	963	1029	1106	1180	1229	1260	...
3: Herma: 3:	0	0	0	0	0	0	0	0	0	...
4: Unknow: 9:	0	0	0	0	0	0	0	0	0	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	0	0	0	0	0	0	0	0	0	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Male: 1:	1503	1641	1689	1722	1758	1775	1785	50	0	:	21775
2: Female: 2:	1500	1572	1528	1631	1724	1647	1639	58	0	:	20634
3: Herma: 3:	0	0	0	0	0	0	0	0	0	:	0
4: Unknow: 9:	0	0	0	0	0	0	0	0	0	:	0
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	0	0	0	0	0	0	0	0	0	:	0

											42409

Number of cases by year by Summary Stage

Frequencies by Year CanReg4 26/08/2016
Number of cases by year by Stage

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: In situ: 0:	69	47	28	40	60	71	76	82	74	...
2: Local (I): 1:	908	775	855	802	861	900	1037	958	967	...
3: Reg DE: 2:	83	192	174	183	169	193	191	205	230	...
4: Reg LN: 3:	175	164	125	144	131	144	136	146	150	...
5: Reg Both: 4:	43	83	115	110	97	95	110	123	185	...
6: Reg NOS (II): 5:	1	15	15	28	11	35	25	11	17	...
7: Dist (III/IV: 7:	283	246	275	295	350	368	411	413	424	...
8: Unknown: 9:	113	150	213	361	447	436	497	617	624	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	0	0	0	0	0	0	0	0	0	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: In situ: 0:	122	101	135	130	104	95	130	4	0	:	1368
2: Local (I): 1:	1019	1019	1032	1058	1075	1129	1111	36	0	:	15542
3: Reg DE: 2:	239	292	243	267	272	282	277	9	0	:	3501
4: Reg LN: 3:	193	221	230	233	253	219	209	6	0	:	2879
5: Reg Both: 4:	166	144	172	157	170	175	166	11	0	:	2122
6: Reg NOS (II): 5:	25	46	20	25	8	6	5	0	0	:	293
7: Dist (III/IV: 7:	530	562	581	534	599	589	559	9	0	:	7028
8: Unknown: 9:	709	828	804	949	1001	927	967	33	0	:	9676
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	0	0	0	0	0	0	0	0	0	:	0
											42409

Number of cases by year by ICD-10 group

Frequencies by Year **CanReg4** **26/08/2016**

Number of cases by year by ICD-10 group

Male

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
Lip	0	3	4	2	2	1	7	3	6	...: C00
Tongue	4	0	5	6	6	6	6	8	3	...: C01-C02
Mouth	4	4	3	3	2	3	5	3	4	...: C03-C06
Salivary glands	2	1	2	3	2	2	0	5	5	...: C07-C08
Tonsil	1	0	2	0	1	1	0	0	3	...: C09
Other Oropharynx	0	0	1	1	5	1	0	1	1	...: C10
Nasopharynx	1	3	1	3	3	4	3	1	1	...: C11
Hypopharynx	1	0	0	1	0	2	0	0	0	...: C12-C13
Pharynx unspec.	0	2	0	0	1	1	0	1	0	...: C14
Oesophagus	4	7	5	5	6	4	2	7	12	...: C15
Stomach	27	28	32	35	46	37	38	37	50	...: C16
Small intestine	2	3	4	3	5	0	1	2	2	...: C17
Colon	62	68	64	74	74	83	112	109	113	...: C18
Rectum	28	32	41	30	41	42	42	41	58	...: C19-C20
Anus	1	2	0	2	1	0	3	0	1	...: C21
Liver	13	16	18	11	22	21	19	25	26	...: C22
Gallbladder etc.	9	12	5	12	8	9	13	9	11	...: C23-C24
Pancreas	19	16	20	21	23	26	26	29	22	...: C25
Nose, sinuses etc.	3	3	0	0	0	0	1	1	2	...: C30-C31
Larynx	19	12	10	17	14	10	18	21	19	...: C32
Trachea,Bronchus,Lung	90	107	119	144	140	137	146	152	148	...: C33-C34
Other Thoracic organs	1	2	0	4	2	9	0	3	3	...: C37-C38
Bone	12	3	3	9	4	8	7	1	6	...: C40-C41
Melanoma of Skin	10	11	13	12	18	13	14	19	16	...: C43
Other Skin	0	0	0	0	0	0	0	0	0	...: C44
Mesothelioma	2	1	3	4	1	6	5	3	10	...: C45
Kaposi sarcoma	2	3	4	0	2	0	3	3	2	...: C46
Connective,Soft tissue	10	7	2	12	7	11	11	12	13	...: C47;C49
Breast	2	6	3	0	3	3	4	4	8	...: C50
Vulva	0	0	0	0	0	0	0	0	0	...: C51
Vagina	0	0	0	0	0	0	0	0	0	...: C52
Cervix Uteri	0	0	0	0	0	0	0	0	0	...: C53
Corpus Uteri	0	0	0	0	0	0	0	0	0	...: C54
Uterus unspec.	0	0	0	0	0	0	0	0	0	...: C55
Ovary	0	0	0	0	0	0	0	0	0	...: C56
Other Female Genital	0	0	0	0	0	0	0	0	0	...: C57
Placenta	0	0	0	0	0	0	0	0	0	...: C58
Penis	5	3	3	4	2	3	7	6	6	...: C60
Prostate	166	162	259	250	267	260	363	360	358	...: C61
Testis	11	17	16	17	15	26	30	25	23	...: C62
Other male genital	0	1	0	1	0	0	0	1	0	...: C63
Kidney	23	15	23	27	29	24	29	25	30	...: C64
Renal Pelvis	2	1	1	0	2	3	1	3	2	...: C65
Ureter	1	0	0	0	0	3	1	2	3	...: C66
Bladder	71	88	108	85	84	105	90	113	124	...: C67
Other Urinary organs	2	1	0	4	1	3	1	1	2	...: C68
Eye	1	0	3	2	0	1	3	1	2	...: C69
Brain, Nervous system	23	17	24	16	20	20	26	13	31	...: C70-C72
Thyroid	12	7	10	15	13	17	18	16	19	...: C73
Adrenal gland	2	1	3	0	2	0	2	1	0	...: C74
Other Endocrine	0	0	0	0	1	0	0	0	0	...: C75
Hodgkin disease	8	8	9	14	11	15	9	21	19	...: C81
Non-Hodgkin lymphoma	45	47	41	29	44	59	63	60	61	...: C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	...: C88
Multiple Myeloma	15	14	6	4	14	19	24	20	21	...: C90
Lymphoid Leukaemia	22	25	19	21	27	21	34	36	30	...: C91
Myeloid Leukaemia	10	21	12	11	13	8	21	17	21	...: C92-C94
Leukaemia unspec.	1	2	4	9	7	5	4	9	5	...: C95
Other & unspecified	27	26	29	61	83	78	55	52	57	...: Other
All sites Total	776	808	934	984	1074	1110	1267	1282	1359	...
All sites but C44	776	808	934	984	1074	1110	1267	1282	1359	...
Non-Malignant	35	18	8	16	23	26	36	44	52	...

Male

	2007	2008	2009	2010	2011	2012	2013	2014	2015			
Lip	9	6	2	4	5	2	2	0	0	:	58:	C00
Tongue	2	10	6	7	11	6	9	0	0	:	95:	C01-C02
Mouth	9	6	6	8	2	8	6	0	0	:	76:	C03-C06
Salivary glands	3	4	4	4	5	7	2	0	0	:	51:	C07-C08
Tonsil	2	3	1	2	2	3	3	0	0	:	24:	C09
Other Oropharynx	0	2	0	1	3	2	1	1	0	:	20:	C10
Nasopharynx	2	7	5	2	3	2	1	0	0	:	42:	C11
Hypopharynx	1	0	2	0	0	1	1	0	0	:	9:	C12-C13
Pharynx unspec.	0	0	0	1	0	0	0	0	0	:	6:	C14
Oesophagus	10	6	8	12	3	5	9	0	0	:	105:	C15
Stomach	51	53	55	45	44	59	46	3	0	:	686:	C16
Small intestine	2	4	5	5	2	4	3	0	0	:	47:	C17
Colon	131	125	148	164	141	175	137	7	0	:	1787:	C18
Rectum	55	65	45	55	82	71	64	4	0	:	796:	C19-C20
Anus	4	2	6	4	0	1	0	1	0	:	28:	C21
Liver	34	26	34	27	33	40	30	0	0	:	395:	C22
Gallbladder etc.	13	8	8	12	12	14	14	0	0	:	169:	C23-C24
Pancreas	36	32	43	43	49	47	42	1	0	:	495:	C25
Nose, sinuses etc.	2	1	2	2	1	3	3	0	0	:	24:	C30-C31
Larynx	25	36	26	28	27	36	24	0	0	:	342:	C32
Trachea,Bronchus,Lung	173	204	233	216	244	232	253	7	0	:	2745:	C33-C34
Other Thoracic organs	5	5	5	2	2	3	2	0	0	:	48:	C37-C38
Bone	5	5	7	7	5	5	3	0	0	:	90:	C40-C41
Melanoma of Skin	30	35	29	33	33	32	45	0	0	:	363:	C43
Other Skin	0	0	0	0	0	0	0	0	0	:	0:	C44
Mesothelioma	7	10	10	7	9	8	6	0	0	:	92:	C45
Kaposi sarcoma	1	4	3	3	1	2	2	0	0	:	35:	C46
Connective,Soft tissue	19	17	14	13	14	13	7	1	0	:	183:	C47;C49
Breast	5	7	5	3	6	8	10	0	0	:	77:	C50
Vulva	0	0	0	0	0	0	0	0	0	:	0:	C51
Vagina	0	0	0	0	0	0	0	0	0	:	0:	C52
Cervix Uteri	0	0	0	0	0	0	0	0	0	:	0:	C53
Corpus Uteri	0	0	0	0	0	0	0	0	0	:	0:	C54
Uterus unspec.	0	0	0	0	0	0	0	0	0	:	0:	C55
Ovary	0	0	0	0	0	0	0	0	0	:	0:	C56
Other Female Genital	0	0	0	0	0	0	0	0	0	:	0:	C57
Placenta	0	0	0	0	0	0	0	0	0	:	0:	C58
Penis	6	11	8	9	6	6	7	0	0	:	92:	C60
Prostate	376	416	423	453	495	489	494	11	0	:	5602:	C61
Testis	24	27	33	25	35	42	32	0	0	:	398:	C62
Other male genital	0	0	0	0	0	1	0	0	0	:	4:	C63
Kidney	18	32	32	43	36	42	40	2	0	:	470:	C64
Renal Pelvis	1	0	0	2	0	1	4	0	0	:	23:	C65
Ureter	2	0	3	1	1	2	1	0	0	:	20:	C66
Bladder	124	140	110	116	127	113	147	2	0	:	1747:	C67
Other Urinary organs	2	1	0	2	1	1	1	0	0	:	23:	C68
Eye	1	0	1	3	2	1	2	0	0	:	23:	C69
Brain, Nervous system	26	25	39	31	23	29	30	2	0	:	395:	C70-C72
Thyroid	21	24	43	39	49	36	49	2	0	:	390:	C73
Adrenal gland	2	4	0	2	1	0	1	0	0	:	21:	C74
Other Endocrine	0	0	1	0	0	0	1	0	0	:	3:	C75
Hodgkin disease	14	18	13	22	13	9	24	1	0	:	228:	C81
Non-Hodgkin lymphoma	50	68	58	62	60	63	70	2	0	:	882:	C82-C85;C96
Immunoproliferative dis.	1	1	0	0	0	1	0	0	0	:	3:	C88
Multiple Myeloma	23	19	29	21	24	19	24	0	0	:	296:	C90
Lymphoid Leukaemia	32	33	36	27	30	22	27	0	0	:	442:	C91
Myeloid Leukaemia	26	30	25	23	14	19	17	1	0	:	289:	C92-C94
Leukaemia unspec.	4	5	2	7	4	4	7	0	0	:	79:	C95
Other & unspecified	52	45	43	46	36	34	30	0	0	:	754:	Other
All sites Total	1441	1582	1611	1644	1696	1723	1733	48	0	:	21072	
All sites but C44	1441	1582	1611	1644	1696	1723	1733	48	0	:	21072	
Non-Malignant	62	59	78	78	62	52	51	2	0	:	702	

Female

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
Lip	0	0	1	1	1	2	1	2	1	...: C00
Tongue	3	4	2	2	6	3	2	4	3	...: C01-C02
Mouth	2	3	1	1	2	2	3	1	1	...: C03-C06
Salivary glands	4	4	0	3	0	2	0	3	1	...: C07-C08
Tonsil	0	0	0	1	0	0	0	1	0	...: C09
Other Oropharynx	0	0	0	0	0	0	0	0	0	...: C10
Nasopharynx	1	2	1	2	1	1	0	1	0	...: C11
Hypopharynx	0	0	0	2	0	1	1	0	0	...: C12-C13
Pharynx unspec.	0	2	1	0	0	1	0	0	0	...: C14
Oesophagus	3	0	3	1	1	4	0	1	3	...: C15
Stomach	27	22	23	25	22	15	23	18	26	...: C16
Small intestine	0	2	0	0	1	0	2	1	1	...: C17
Colon	59	62	72	63	72	67	97	86	100	...: C18
Rectum	19	24	35	29	23	25	26	42	41	...: C19-C20
Anus	1	2	0	1	1	1	1	3	4	...: C21
Liver	5	6	7	4	12	8	7	11	13	...: C22
Gallbladder etc.	13	16	11	16	13	7	11	16	11	...: C23-C24
Pancreas	12	13	16	18	16	10	19	22	23	...: C25
Nose, sinuses etc.	0	0	0	4	2	0	0	0	1	...: C30-C31
Larynx	1	1	2	4	0	2	1	3	3	...: C32
Trachea,Bronchus,Lung	19	27	27	29	37	24	45	44	57	...: C33-C34
Other Thoracic organs	2	3	1	1	3	0	1	0	2	...: C37-C38
Bone	2	3	2	9	6	4	7	4	2	...: C40-C41
Melanoma of Skin	18	14	17	20	19	21	16	16	18	...: C43
Other Skin	0	0	0	0	0	0	0	0	0	...: C44
Mesothelioma	1	3	1	1	1	2	2	3	3	...: C45
Kaposi sarcoma	1	0	1	1	4	1	1	1	1	...: C46
Connective,Soft tissue	12	9	5	5	10	12	13	12	10	...: C47;C49
Breast	280	289	287	323	342	412	408	424	435	...: C50
Vulva	12	5	4	6	10	8	9	8	7	...: C51
Vagina	0	2	2	1	2	0	0	1	2	...: C52
Cervix Uteri	27	26	15	18	19	18	27	25	30	...: C53
Corpus Uteri	50	47	72	56	55	70	67	83	72	...: C54
Uterus unspec.	8	1	4	5	4	3	4	10	8	...: C55
Ovary	47	36	33	40	34	24	41	36	36	...: C56
Other Female Genital	0	0	0	0	1	1	0	1	2	...: C57
Placenta	0	0	0	0	0	0	0	1	0	...: C58
Penis	0	0	0	0	0	0	0	0	0	...: C60
Prostate	0	0	0	0	0	0	0	0	0	...: C61
Testis	0	0	0	0	0	0	0	0	0	...: C62
Other male genital	0	0	0	0	0	0	0	0	0	...: C63
Kidney	8	16	13	11	18	17	10	11	14	...: C64
Renal Pelvis	1	0	0	0	0	1	0	1	0	...: C65
Ureter	0	0	0	2	0	1	0	0	0	...: C66
Bladder	16	18	13	16	21	15	27	23	17	...: C67
Other Urinary organs	0	1	1	0	0	1	0	0	0	...: C68
Eye	3	0	2	0	1	1	1	4	2	...: C69
Brain, Nervous system	18	16	20	23	16	19	15	14	22	...: C70-C72
Thyroid	44	34	34	43	40	56	50	53	70	...: C73
Adrenal gland	0	0	2	1	0	2	0	3	3	...: C74
Other Endocrine	0	1	0	1	0	0	0	0	0	...: C75
Hodgkin disease	10	12	11	17	12	16	15	13	16	...: C81
Non-Hodgkin lymphoma	33	36	29	24	38	37	44	44	49	...: C82-C85;C96
Immunoproliferative dis.	0	0	0	0	0	0	1	0	0	...: C88
Multiple Myeloma	7	8	5	9	15	17	22	17	10	...: C90
Lymphoid Leukaemia	17	14	10	16	11	18	32	31	23	...: C91
Myeloid Leukaemia	10	11	11	10	9	12	15	16	17	...: C92-C94
Leukaemia unspec.	3	3	2	6	10	8	1	1	3	...: C95
Other & unspecified	31	19	38	59	75	73	55	54	44	...: Other
All sites Total	830	817	837	930	986	1045	1123	1169	1207	...
All sites but C44	830	817	837	930	986	1045	1123	1169	1207	...
Non-Malignant	34	29	21	33	43	61	57	60	53	...

Female

	2007	2008	2009	2010	2011	2012	2013	2014	2015			
Lip	0	1	4	2	3	0	0	0	0	:	19:	C00
Tongue	4	3	3	5	2	7	7	1	0	:	61:	C01-C02
Mouth	4	4	6	5	4	3	1	0	0	:	43:	C03-C06
Salivary glands	4	4	4	0	5	3	2	0	0	:	39:	C07-C08
Tonsil	1	1	0	2	1	1	3	0	0	:	11:	C09
Other Oropharynx	0	0	1	0	0	0	0	0	0	:	1:	C10
Nasopharynx	1	2	2	2	0	1	0	0	0	:	17:	C11
Hypopharynx	1	0	1	1	0	0	1	0	0	:	8:	C12-C13
Pharynx unspec.	0	0	0	0	0	0	0	0	0	:	4:	C14
Oesophagus	4	6	7	1	4	1	0	0	0	:	39:	C15
Stomach	29	43	42	38	40	35	43	3	0	:	474:	C16
Small intestine	2	3	6	4	2	0	3	1	0	:	28:	C17
Colon	140	96	116	134	124	114	113	6	0	:	1521:	C18
Rectum	40	39	33	35	37	34	30	2	0	:	514:	C19-C20
Anus	5	4	2	6	6	4	1	0	0	:	42:	C21
Liver	16	11	18	11	17	15	22	0	0	:	183:	C22
Gallbladder etc.	11	13	15	10	18	12	13	0	0	:	206:	C23-C24
Pancreas	33	34	24	28	34	32	25	0	0	:	359:	C25
Nose, sinuses etc.	3	0	0	1	1	0	1	0	0	:	13:	C30-C31
Larynx	1	1	3	1	1	3	2	0	0	:	29:	C32
Trachea,Bronchus,Lung	48	64	62	62	73	63	68	2	0	:	751:	C33-C34
Other Thoracic organs	6	3	2	2	0	3	3	0	0	:	32:	C37-C38
Bone	3	0	7	9	6	2	2	0	0	:	68:	C40-C41
Melanoma of Skin	30	38	28	24	33	26	34	0	0	:	372:	C43
Other Skin	0	0	0	0	0	0	0	0	0	:	0:	C44
Mesothelioma	1	1	2	2	1	5	4	1	0	:	34:	C45
Kaposi sarcoma	1	1	0	1	2	0	0	0	0	:	16:	C46
Connective,Soft tissue	8	19	17	12	19	14	6	0	0	:	183:	C47;C49
Breast	507	512	473	527	574	542	546	7	0	:	6888:	C50
Vulva	9	9	12	11	12	7	8	0	0	:	137:	C51
Vagina	1	0	4	0	4	1	0	0	0	:	20:	C52
Cervix Uteri	32	28	29	39	27	38	40	0	0	:	438:	C53
Corpus Uteri	71	85	84	102	91	94	94	2	0	:	1195:	C54
Uterus unspec.	3	10	7	3	4	4	4	0	0	:	82:	C55
Ovary	49	57	68	50	68	41	66	1	0	:	727:	C56
Other Female Genital	3	4	1	1	0	4	0	0	0	:	18:	C57
Placenta	0	0	0	0	0	0	0	0	0	:	1:	C58
Penis	0	0	0	0	0	0	0	0	0	:	0:	C60
Prostate	0	0	0	0	0	0	0	0	0	:	0:	C61
Testis	0	0	0	0	0	0	0	0	0	:	0:	C62
Other male genital	0	0	0	0	0	0	0	0	0	:	0:	C63
Kidney	11	22	13	18	24	30	21	0	0	:	257:	C64
Renal Pelvis	1	2	2	2	1	0	1	0	0	:	12:	C65
Ureter	0	1	0	0	1	0	1	0	0	:	6:	C66
Bladder	25	31	18	25	25	22	26	2	0	:	340:	C67
Other Urinary organs	0	0	1	0	0	0	0	0	0	:	4:	C68
Eye	1	2	0	1	4	1	2	0	0	:	25:	C69
Brain, Nervous system	29	28	21	23	23	30	15	0	0	:	332:	C70-C72
Thyroid	85	124	133	161	182	200	168	23	0	:	1500:	C73
Adrenal gland	2	0	0	0	1	1	0	0	0	:	15:	C74
Other Endocrine	1	0	0	0	0	0	0	0	0	:	3:	C75
Hodgkin disease	9	18	16	16	18	19	24	1	0	:	243:	C81
Non-Hodgkin lymphoma	52	58	63	74	64	57	66	3	0	:	771:	C82-C85;C96
Immunoproliferative dis.	0	0	1	0	0	0	2	0	0	:	4:	C88
Multiple Myeloma	28	29	16	21	17	25	20	1	0	:	267:	C90
Lymphoid Leukaemia	19	21	11	14	18	23	16	0	0	:	294:	C91
Myeloid Leukaemia	13	13	21	17	20	18	13	0	0	:	226:	C92-C94
Leukaemia unspec.	4	4	3	3	5	6	2	0	0	:	64:	C95
Other & unspecified	52	50	43	24	26	31	29	0	0	:	703:	Other
All sites Total	1403	1499	1445	1530	1642	1572	1548	56	0	:	19639	
All sites but C44	1403	1499	1445	1530	1642	1572	1548	56	0	:	19639	
Non-Malignant	97	73	83	101	82	75	91	2	0	:	995	

Number of cases by year by Cause of death

```
       Frequencies by Year                CanReg4          26/08/2016
Number of cases by year by Cause


                 1998 1999 2000 2001 2002 2003 2004 2005 2006
                 ---- ---- ---- ---- ---- ---- ---- ---- ----
1:  Alive: 0:     768  752  734  806  835  987 1135 1232 1345 ...
2: Cancer: 1:     464  577  674  803  879  906 1058 1070 1034 ...
3: Non Ca: 2:     159  193  273  256  287  203  227  184  226 ...
4: Unknow: 9:     284  150  119   98  125  146   63   69   66 ...
      Errors:       0    0    0    0    0    0    0    0    0 ...
     Missing:       0    0    0    0    0    0    0    0    0 ...


                 2007 2008 2009 2010 2011 2012 2013 2014 2015
                 ---- ---- ---- ---- ---- ---- ---- ---- ----
1:  Alive: 0:    1550 1759 1825 2009 2084 2175 2315   88    0 :  22399
2: Cancer: 1:    1142 1141 1101 1058 1084  952  826   11    0 :  14780
3: Non Ca: 2:     233  214  202  174  160  135  109    3    0 :   3238
4: Unknow: 9:      78   99   89  112  154  160  174    6    0 :   1992
      Errors:       0    0    0    0    0    0    0    0    0 :      0
     Missing:       0    0    0    0    0    0    0    0    0 :      0
                                                               -------
                                                                 42409
```

Number of cases by year by Vital Status

```
Frequencies by Year                CanReg4          26/08/2016

Number of cases by year by Status


                1998 1999 2000 2001 2002 2003 2004 2005 2006
                ---- ---- ---- ---- ---- ---- ---- ---- ----
1: Alive: 0:     768  752  734  806  835  987 1135 1232 1345 ...
2:  Dead: 1:     907  920 1066 1157 1291 1255 1348 1323 1326 ...

     Errors:       0    0    0    0    0    0    0    0    0 ...
    Missing:       0    0    0    0    0    0    0    0    0 ...


                2007 2008 2009 2010 2011 2012 2013 2014 2015
                ---- ---- ---- ---- ---- ---- ---- ---- ----
1: Alive: 0:    1550 1759 1825 2009 2084 2175 2309   89    0 :  22394
2:  Dead: 1:    1453 1454 1392 1344 1398 1247 1115   19    0 :  20015

     Errors:       0    0    0    0    0    0    0    0    0 :      0
    Missing:       0    0    0    0    0    0    0    0    0 :      0

                                                              -------
                                                                42409
```

Number of cases by year by Month of incidence

```
 Frequencies by Year               CanReg4          26/08/2016
Number of cases by year by Month


      unk  Jan  Feb  Mar  Apr  May  Jun  Jul  Aug  Sep  Oct  Nov  Dec  TOT
1998   10  129  145  143  138  143  171  154  115  128  126  121  152 1675
1999    7  109  123  149  139  138  156  159  116  117  132  176  151 1672
2000   18  133  155  144  141  161  156  151  130  153  159  175  124 1800
2001   15  148  141  186  135  179  179  183  142  155  197  178  125 1963
2002   15  138  180  189  194  179  181  213  141  170  179  188  159 2126
2003   14  160  167  172  175  213  178  196  144  209  226  205  183 2242
2004   20  181  195  236  204  213  250  214  162  205  196  230  177 2483
2005   16  210  189  219  198  184  289  224  176  210  216  222  202 2555
2006   12  220  217  239  168  244  263  214  202  220  243  223  206 2671
2007   16  232  228  309  225  289  251  248  176  255  274  282  218 3003
2008   16  277  253  251  275  325  286  291  217  270  258  265  229 3213
2009   15  250  268  279  216  304  280  278  225  286  282  271  263 3217
2010    6  258  260  313  264  315  297  284  232  305  258  288  273 3353
2011    4  250  248  321  276  329  341  268  274  294  302  307  268 3482
2012    2  269  282  314  251  312  267  320  231  300  329  290  255 3422
2013    3  295  272  248  333  297  291  315  240  271  296  313  250 3424
2014    0   37   14    4    3    8    9   10    4    7    0    7    5  108
2015    0    0    0    0    0    0    0    0    0    0    0    0    0    0
     ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- -----
      189 3296 3337 3716 3335 3833 3845 3722 2927 3555 3673 3741 3240 42409
```

Number of cases by year by Cancer Therapy

Frequencies by Year CanReg4 26/08/2016
Number of cases by year by The

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Not Given: 0:	0	0	0	0	0	0	0	0	0	...
2: Given: 1:	40	109	186	253	467	835	903	928	1017	...
3: Refused: 7:	0	0	0	0	0	0	0	0	0	...
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	...
5: Unknown: 9:	39	0	0	1	4	4	5	1620	1647	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	1596	1563	1614	1709	1655	1403	1575	7	7	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Not Given: 0:	1	1	99	106	123	154	187	2	0	:	673
2: Given: 1:	1256	2448	2447	2494	2615	2665	2643	100	0	:	21406
3: Refused: 7:	0	1	4	4	6	2	3	0	0	:	20
4: Recomm: 8:	0	1	1	0	3	0	0	0	0	:	5
5: Unknown: 9:	1739	760	666	747	735	601	585	6	0	:	9159
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	7	2	0	2	0	0	6	0	0	:	11146
											42409

Number of cases by year by Cancer Surgery

Frequencies by Year CanReg4 26/08/2016
Number of cases by year by Sur

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Not Given: 0:	0	0	0	0	0	0	1	0	1	...
2: Given: 1:	0	1	0	0	1	2	2	4	17	...
3: Refused: 7:	0	0	0	0	0	0	0	0	0	...
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	...
5: Unknown: 9:	0	1	0	5	3	6	7	2543	2642	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	1675	1670	1800	1958	2122	2234	2473	8	11	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Not Given: 0:	11	76	613	743	862	882	974	29	0	:	4192
2: Given: 1:	129	1764	1772	1807	1816	1895	1892	74	0	:	11176
3: Refused: 7:	0	4	4	7	1	3	2	0	0	:	21
4: Recomm: 8:	0	0	0	0	3	1	1	0	0	:	5
5: Unknown: 9:	2851	1367	827	794	799	641	548	5	0	:	13039
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	12	2	1	2	1	0	7	0	0	:	13976
											42409

Number of cases by year by Radiotherapy

```
  Frequencies by Year              CanReg4          26/08/2016
Number of cases by year by Rad
```

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Not Given: 0:	0	0	0	0	0	1	1	0	498	...
2: Given: 1:	24	67	110	136	366	766	822	823	882	...
3: Refused: 7:	0	0	0	0	0	0	0	0	0	...
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	...
5: Unknown: 9:	0	0	0	2	3	6	5	1724	1281	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	1651	1605	1690	1825	1757	1469	1655	8	10	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Not Given: 0:	519	561	869	991	1082	1330	1581	75	0	:	7508
2: Given: 1:	1001	1093	1125	1233	1331	1239	1179	25	0	:	12222
3: Refused: 7:	0	0	1	3	5	5	4	0	0	:	18
4: Recomm: 8:	0	0	1	0	2	4	0	0	0	:	7
5: Unknown: 9:	1473	1557	1220	1124	1060	842	652	8	0	:	10957
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	10	2	1	2	2	2	8	0	0	:	11697
											42409

Number of cases by year by Chemotherapy

```
  Frequencies by Year              CanReg4          26/08/2016
Number of cases by year by Che
```

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Not Given: 0:	0	0	0	1	0	0	2	1	4	...
2: Given: 1:	5	25	36	37	52	65	78	86	108	...
3: Refused: 7:	0	0	0	0	0	0	0	0	0	...
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	...
5: Unknown: 9:	0	0	0	2	3	5	4	2460	2547	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	1670	1647	1764	1923	2071	2172	2399	8	12	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Not Given: 0:	20	216	725	977	1062	1402	1603	63	0	:	6076
2: Given: 1:	224	1142	1120	1105	1178	1163	1095	35	0	:	7554
3: Refused: 7:	0	6	4	8	6	5	5	0	0	:	34
4: Recomm: 8:	0	1	3	3	2	4	0	0	0	:	13
5: Unknown: 9:	2749	1846	1364	1258	1231	846	712	10	0	:	15037
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	10	2	1	2	3	2	9	0	0	:	13695
											42409

Number of cases by year by Hormone therapy

```
  Frequencies by Year              CanReg4          26/08/2016
Number of cases by year by Hor
```

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Not Given: 0:	0	0	0	0	0	1	2	0	4	...
2: Given: 1:	18	49	93	140	135	200	282	306	356	...
3: Refused: 7:	0	0	0	0	0	0	0	0	0	...
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	...
5: Unknown: 9:	0	0	0	4	3	5	5	2242	2300	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	1657	1623	1707	1819	1988	2036	2194	7	11	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Not Given: 0:	13	209	1029	1378	1515	1674	1888	66	0	:	7779
2: Given: 1:	492	1161	814	779	840	788	819	34	0	:	7306
3: Refused: 7:	0	1	0	1	0	3	2	0	0	:	7
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	:	0
5: Unknown: 9:	2488	1840	1373	1193	1125	955	707	8	0	:	14248
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	10	2	1	2	2	2	8	0	0	:	13069
											42409

Number of cases by year by Immunotherapy

Frequencies by Year CanReg4 26/08/2016
Number of cases by year by Imm

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Not Given: 0:	0	0	0	1	0	1	4	1	6	...
2: Given: 1:	1	5	9	11	12	16	21	24	22	...
3: Refused: 7:	0	0	0	0	0	0	0	0	0	...
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	...
5: Unknown: 9:	0	1	0	4	3	6	6	2522	2630	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	1674	1666	1791	1947	2111	2219	2452	8	13	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Not Given: 0:	27	103	1317	1900	2105	2447	2706	99	0	:	10717
2: Given: 1:	44	80	135	162	140	140	106	3	0	:	931
3: Refused: 7:	0	0	0	1	1	1	0	0	0	:	3
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	:	0
5: Unknown: 9:	2921	3028	1764	1287	1233	832	602	6	0	:	16845
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	11	2	1	3	3	2	10	0	0	:	13913
											42409

Number of cases by year by Other therapy

Frequencies by Year CanReg4 26/08/2016
Number of cases by year by Oth

	1998	1999	2000	2001	2002	2003	2004	2005	2006	
1: Not Given: 0:	0	0	0	1	0	1	4	1	6	...
2: Given: 1:	0	0	0	0	0	0	0	0	0	...
3: Refused: 7:	0	0	0	0	0	0	0	0	0	...
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	...
5: Unknown: 9:	0	1	0	4	3	6	6	2546	2652	...
Errors:	0	0	0	0	0	0	0	0	0	...
Missing:	1675	1671	1800	1958	2123	2235	2473	8	13	...

	2007	2008	2009	2010	2011	2012	2013	2014	2015		
1: Not Given: 0:	27	111	1402	2062	2229	2579	2803	102	0	:	11328
2: Given: 1:	0	0	2	0	14	8	10	0	0	:	34
3: Refused: 7:	0	0	0	1	1	1	0	0	0	:	3
4: Recomm: 8:	0	0	0	0	0	0	0	0	0	:	0
5: Unknown: 9:	2964	3100	1812	1287	1235	832	601	6	0	:	17055
Errors:	0	0	0	0	0	0	0	0	0	:	0
Missing:	12	2	1	3	3	2	10	0	0	:	13989
											42409

Number of cases by year by Topography

Frequencies by Year **CanReg4** **26/08/2016**

Number of cases by year by Topo

			1998	1999	2000	2001	2002	2003	2004	2005	2006	
1:	LIP:	00:	0	3	5	3	3	3	9	5	7	...
2:	TONGUE - BA:	01:	3	0	1	4	8	4	0	5	2	...
3:	TONGUE - OT:	02:	4	4	7	4	6	7	9	7	5	...
4:	GUM:	03:	1	0	0	0	0	0	2	1	1	...
5:	MOUTH - FLO:	04:	0	0	1	2	1	0	0	1	1	...
6:	MOUTH - PAL:	05:	3	3	2	1	1	1	2	0	2	...
7:	MOUTH - OTH:	06:	2	4	1	1	2	4	5	2	2	...
8:	MOUTH - PAR:	07:	4	2	3	5	1	5	0	4	5	...
9:	MOUTH - GLA:	08:	2	4	2	1	1	0	1	5	1	...
10:	TONSILS:	09:	2	0	2	2	5	1	1	4	4	...
11:	OROPHARYNX:	10:	0	0	1	1	5	2	0	1	1	...
12:	NASOPHARYNX:	11:	2	5	2	5	5	7	3	3	1	...
13:	PYRIFORM SI:	12:	0	0	0	2	0	0	0	0	0	...
14:	HYPOPHARYNX:	13:	1	0	0	1	0	3	1	0	0	...
15:	OTHER PHARY:	14:	0	4	1	0	2	2	0	1	0	...
16:	ESOPHAGUS:	15:	7	8	8	6	7	8	2	8	15	...
17:	STOMACH:	16:	61	56	62	63	75	60	70	61	86	...
18:	SMALL INTES:	17:	3	5	4	3	6	2	4	3	4	...
19:	COLON:	18:	124	130	137	139	147	151	214	198	216	...
20:	RECTOSIGMOI:	19:	7	9	16	16	12	24	23	23	32	...
21:	RECTUM:	20:	40	49	60	43	52	44	46	61	68	...
22:	ANUS, ANAL :	21:	2	5	0	3	2	1	4	3	6	...
23:	LIVER:	22:	20	22	26	16	34	29	26	35	40	...
24:	GALL BLADDE:	23:	20	24	15	25	19	9	15	13	11	...
25:	BILE TRACT:	24:	2	4	1	3	5	7	9	15	11	...
26:	PANCREAS:	25:	31	29	36	39	39	36	45	51	45	...
27:	GASTROINTES:	26:	1	3	2	5	10	4	3	9	7	...
28:	EAR/NOSE:	30:	3	4	0	3	2	0	1	1	3	...
29:	ACCESSORY S:	31:	0	1	0	1	0	0	0	0	1	...
30:	LARYNX:	32:	20	16	14	22	16	13	21	27	23	...
31:	TRACHEA:	33:	0	0	0	0	0	0	0	0	0	...
32:	BRONCHUS, L:	34:	112	135	147	173	178	163	191	196	206	...
33:	THYMUS:	37:	0	0	1	2	3	4	1	0	1	...
34:	HEART, PLEU:	38:	7	11	5	11	7	14	8	13	18	...
35:	RESPIRATORY:	39:	0	0	0	0	0	0	0	0	0	...
36:	BONES - LIM:	40:	7	4	2	8	5	4	6	2	4	...
37:	BONES - OTH:	41:	6	2	3	9	5	8	8	6	2	...
38:	BLOOD, SPLE:	42:	86	102	72	95	111	126	173	167	164	...
39:	SKIN:	44:	33	31	37	42	46	41	41	43	43	...
40:	PERIPHERAL :	47:	2	1	0	0	1	1	1	0	0	...
41:	PERITONEUM:	48:	5	5	3	0	2	4	3	4	5	...
42:	SOFT TISSUE:	49:	20	10	7	12	13	19	19	22	23	...
43:	BREAST:	50:	297	311	306	348	377	457	452	468	468	...
44:	VULVA:	51:	12	5	4	6	10	8	10	8	7	...
45:	VAGINA:	52:	0	2	2	1	2	0	0	1	2	...
46:	CERVIX UTER:	53:	33	34	18	22	27	28	28	33	37	...
47:	CORPUS UTER:	54:	51	48	74	57	56	70	67	83	72	...
48:	UTERUS, NOS:	55:	8	1	4	5	4	3	4	10	8	...
49:	OVARY:	56:	47	36	33	40	34	24	41	35	36	...
50:	FEMALE GEN.:	57:	1	0	0	0	1	1	0	1	2	...
51:	PLACENTA:	58:	0	0	0	0	0	0	0	1	0	...
52:	PENIS:	60:	5	3	3	4	2	3	7	6	7	...
53:	PROSTATE:	61:	166	162	262	250	268	261	363	360	359	...
54:	TESTIS:	62:	12	17	16	17	19	28	32	25	25	...
55:	MALE GEN.- :	63:	0	1	0	1	0	0	0	1	0	...
56:	KIDNEY:	64:	33	33	37	38	47	41	39	36	44	...
57:	RENAL PELVI:	65:	3	1	1	0	2	4	1	4	2	...
58:	URETER:	66:	1	0	0	2	0	4	1	2	3	...
59:	BLADDER:	67:	132	122	123	108	113	132	136	166	171	...
60:	URETHRA, OT:	68:	2	2	1	4	1	4	1	1	2	...
61:	EYE:	69:	4	0	5	3	4	2	4	7	7	...
62:	MENINGES:	70:	2	0	1	0	0	0	2	0	0	...
63:	BRAIN:	71:	36	34	39	35	37	39	37	27	54	...
64:	NERVOUS SYS:	72:	3	1	4	4	0	1	2	0	1	...
65:	THYROID:	73:	56	41	44	58	53	74	68	69	89	...
66:	ADRENAL GLA:	74:	2	0	4	1	2	2	1	4	3	...
67:	ENDOCRINE G:	75:	0	1	0	1	1	0	0	0	0	...
68:	ILL-DEFINED:	76:	2	3	4	4	3	3	7	10	7	...
69:	LYMPH NODES:	77:	70	70	66	69	79	96	112	106	108	...
70:	UNKNOWN:	80:	54	49	63	114	147	146	101	91	91	...
	Errors:		0	0	0	0	0	0	0	0	0	...
	Missing:		0	0	0	0	0	0	0	0	0	...

			2007	2008	2009	2010	2011	2012	2013	2014	2015		
1:	LIP:	00:	9	7	7	6	8	2	2	0	0	:	79
2:	TONGUE - BA:	01:	1	2	1	2	0	0	2	0	0	:	35
3:	TONGUE - OT:	02:	5	12	8	12	14	14	15	1	0	:	134
4:	GUM:	03:	0	1	1	3	2	1	1	0	0	:	14
5:	MOUTH - FLO:	04:	2	1	2	2	0	4	1	0	0	:	18
6:	MOUTH - PAL:	05:	4	2	3	2	0	2	2	0	0	:	30
7:	MOUTH - OTH:	06:	8	6	6	6	4	4	3	0	0	:	60
8:	MOUTH - PAR:	07:	6	6	8	4	8	5	3	0	0	:	69
9:	MOUTH - GLA:	08:	2	2	1	1	2	5	1	0	0	:	31
10:	TONSILS:	09:	4	5	4	6	6	5	9	0	0	:	60
11:	OROPHARYNX:	10:	0	2	1	1	3	2	1	1	0	:	22
12:	NASOPHARYNX:	11:	4	11	7	4	3	5	3	0	0	:	70
13:	PYRIFORM SI:	12:	0	0	0	0	0	0	0	0	0	:	2
14:	HYPOPHARYNX:	13:	2	0	3	1	0	1	2	0	0	:	15
15:	OTHER PHARY:	14:	0	0	0	1	0	0	0	0	0	:	11
16:	ESOPHAGUS:	15:	14	12	15	13	7	7	9	0	0	:	146
17:	STOMACH:	16:	84	102	106	94	90	98	101	6	0	:	1275
18:	SMALL INTES:	17:	6	8	14	12	6	4	8	1	0	:	93
19:	COLON:	18:	274	224	276	306	272	296	255	14	0	:	3373
20:	RECTOSIGMOI:	19:	24	27	19	21	18	15	14	2	0	:	302
21:	RECTUM:	20:	71	79	61	71	102	90	80	4	0	:	1021
22:	ANUS, ANAL :	21:	9	6	8	10	6	5	1	1	0	:	72
23:	LIVER:	22:	50	36	52	37	50	54	53	0	0	:	580
24:	GALL BLADDE:	23:	16	16	8	12	18	11	12	0	0	:	244
25:	BILE TRACT:	24:	10	7	15	11	13	17	16	0	0	:	146
26:	PANCREAS:	25:	69	67	68	73	83	80	67	1	0	:	859
27:	GASTROINTES:	26:	1	9	2	3	0	1	6	0	0	:	66
28:	EAR/NOSE:	30:	4	0	2	2	0	2	4	0	0	:	31
29:	ACCESSORY S:	31:	1	1	0	2	2	1	0	0	0	:	10
30:	LARYNX:	32:	27	38	33	30	31	40	27	0	0	:	398
31:	TRACHEA:	33:	0	0	1	0	0	0	0	0	0	:	1
32:	BRONCHUS, L:	34:	221	269	296	279	317	299	323	9	0	:	3514
33:	THYMUS:	37:	5	5	5	4	2	5	4	0	0	:	42
34:	HEART, PLEU:	38:	16	18	18	10	10	18	14	0	0	:	198
35:	RESPIRATORY:	39:	0	0	0	0	0	0	0	0	0	:	0
36:	BONES - LIM:	40:	6	4	3	3	2	3	2	0	0	:	65
37:	BONES - OTH:	41:	2	2	8	7	6	4	2	0	0	:	80
38:	BLOOD, SPLE:	42:	189	185	170	187	177	171	147	2	0	:	2324
39:	SKIN:	44:	68	93	71	73	77	73	97	1	0	:	910
40:	PERIPHERAL :	47:	0	0	0	0	0	0	0	0	0	:	6
41:	PERITONEUM:	48:	3	10	9	6	7	4	6	0	0	:	76
42:	SOFT TISSUE:	49:	26	31	28	31	32	20	10	0	0	:	323
43:	BREAST:	50:	568	567	523	582	631	597	615	8	0	:	7575
44:	VULVA:	51:	10	10	13	11	12	7	8	0	0	:	141
45:	VAGINA:	52:	1	0	4	0	4	1	0	0	0	:	20
46:	CERVIX UTER:	53:	41	35	35	48	32	43	55	0	0	:	549
47:	CORPUS UTER:	54:	72	85	87	104	92	95	94	2	0	:	1209
48:	UTERUS, NOS:	55:	3	10	7	3	5	4	4	0	0	:	83
49:	OVARY:	56:	49	57	69	50	68	41	67	1	0	:	728
50:	FEMALE GEN.:	57:	3	4	1	1	0	4	0	0	0	:	19
51:	PLACENTA:	58:	0	0	0	0	0	0	0	0	0	:	1
52:	PENIS:	60:	7	12	9	9	6	7	7	0	0	:	97
53:	PROSTATE:	61:	376	416	423	453	496	489	494	11	0	:	5609
54:	TESTIS:	62:	25	28	34	26	37	43	39	0	0	:	423
55:	MALE GEN.- :	63:	0	0	0	0	0	1	0	0	0	:	4
56:	KIDNEY:	64:	29	56	47	62	61	74	63	2	0	:	742
57:	RENAL PELVI:	65:	2	3	2	4	1	1	5	0	0	:	36
58:	URETER:	66:	3	1	3	1	2	3	2	0	0	:	28
59:	BLADDER:	67:	191	208	186	186	186	161	213	7	0	:	2541
60:	URETHRA, OT:	68:	2	1	1	2	1	1	1	0	0	:	27
61:	EYE:	69:	2	3	1	5	6	4	7	0	0	:	64
62:	MENINGES:	70:	2	1	0	0	0	0	0	0	0	:	8
63:	BRAIN:	71:	53	52	59	55	46	62	44	2	0	:	711
64:	NERVOUS SYS:	72:	1	1	5	2	3	4	4	0	0	:	36
65:	THYROID:	73:	107	149	176	200	231	236	217	25	0	:	1893
66:	ADRENAL GLA:	74:	3	3	0	1	2	1	2	0	0	:	31
67:	ENDOCRINE G:	75:	1	0	1	0	0	0	1	0	0	:	6
68:	ILL-DEFINED:	76:	12	12	11	10	13	8	9	0	0	:	118
69:	LYMPH NODES:	77:	93	114	102	133	118	105	128	7	0	:	1576
70:	UNKNOWN:	80:	104	79	78	57	51	62	42	0	0	:	1329
	Errors:		0	0	0	0	0	0	0	0	0	:	0
	Missing:		0	0	0	0	0	0	0	0	0	:	0
													42409

APPENDIX III. Trends in World Age Standardised Rates 1998-2013

(Revised 2011 CY Population)

Figure 1. CyCR: Trends in WASR, All but C44



Figure 2. CyCR: Trends in WASR, C16 Stomach



Figure 3. CyCR: Trends in WASR, C18-20 Colorectal



Figure 4. CyCR: Trends in WASR, C33-C34 Tr., Br., Lung



Figure 5. CyCR: Trends in WASR, C50 Breast



Figure 6. CyCR: Trends in WASR, C53 Cervix uteri



Figure 7. CyCR: Trends in WASR, C54 Corpus Uteri



Figure 8. CyCR: Trends in WASR, C56 Ovary



Figure 9. CyCR: Trends in WASR, C61 Prostate



Figure 10. CyCR: Trends in WASR, C62 Testis



Figure 11. CyCR: Trends in WASR, C67 Bladder



Figure 12. CyCR: Trends in WASR, C70-C72 Brain & NS



Figure 13. CyCR: Trends in WASR, C73 Thyroid



Figure 14. CyCR: Trends in WASR, C81 Hodgkin disease



Figure 15. CyCR: Trends in WASR, C82-C85; C96 NHL



Figure 16. CyCR: Trends in WASR, C91 Lymphoid Leukemia



Figure 17. CyCR: Trends in WASR, C92-C94 Myeloid Leukemia



Figure 18. CyCR: Trends in WASR, O&U Other & Unspecified



APPENDIX IV. Childhood Cancer by ICCC 2011-2013

CyCR: International Classification for Childhood Cancer 2011-2013

Incidence Tables

CanReg4 28/08/2016

ChildAvg_2011-2013_Rev2011_World

Date : 28/08/2016

Source : Revised Cyprus Populations 2011

Filter : Beha=3 and (Restat=1 or Restat=9)

Standard pop. : World

Ages	Male	Female	WSP
0	4969	4730	2400
1-4	20177	19232	9600
5-9	23411	22039	10000
10-14	23901	22752	9000
??? :	0	0	
	------	------	------
Total :	72458	68753	31000

Incidence date range:

From 01/01/2011

To 31/12/2013

Incidence date range: From 01/01/2011 To 31/12/2013

International Classification for Childhood Cancer

Male		NUMBER OF CASES					FREQUENCY		RATES PER MILLION					
ICCC		0	1-4	5-9	10-14	All	All	Group	0	1-4	5-9	10-14	Crude	ASR
01	LEUKAEMIA,MYELOPRO/MYELODYS.DIS.		6	4	2	12	46%	100%		99.1	56.9	27.9	55.2	57.2
01a	Lymphoid leukaemia		6	3	2	11	42%	92%		99.1	42.7	27.9	50.6	52.6
01b	Acute myeloid leukaemia			1		1	4%	8%			14.2		4.6	4.6
01c	Chronic myeloproliferative													
01d	Myelodysplas syn, myeloprolif.													
01e	Other/unspec leukaemia													
02	LYMPHOMAS, RETICULOENDOTHELIAL		1	1	1	3	12%	100%		16.5	14.2	13.9	13.8	13.8
02a	Hodgkin lymphoma			1		1	4%	33%			14.2		4.6	4.6
02b	NHL (not Burkitt)													
02c	Burkitt lymphoma		1		1	2	8%	67%		16.5		13.9	9.2	9.2
02d	Misc lymphoreticular													
02e	Unspecified lymphoma													
03	CNS, INTRACRANIAL/SPINAL		1		2	3	12%	100%		16.5		27.9	13.8	13.2
03a	Ependymoma, choroid plexus													
03b	Astrocytoma				1	1	4%	33%				13.9	4.6	4
03c	Intracranial/spinal embryonal		1		1	2	8%	67%		16.5		13.9	9.2	9.2
03d	Other glioma													
03e	Oth.spec.intracranial/spinal													
03f	Unspec.intracranial/spinal													
04	NEUROBLASTOMA,PER.NERV.CELL													
04a	Neuro/ganglioneuroblastoma													
04b	Other periph.nervous cell													
05	RETINOBLASTOMA													
06	RENAL TUMOUR				1	1	4%	100%				13.9	4.6	4
06a	Nephroblastoma, non-epithel.renal				1	1	4%	100%				13.9	4.6	4
06b	Renal carcinomas													
06c	Unspec.malig.renal													
07	HEPATIC TUMOUR													
07a	Hepatoblastoma													
07b	Hepatic carcinoma													
07c	Unspec.malig.hepatic													
08	MALIGNANT BONE TUMOUR				2	2	8%	100%				27.9	9.2	8.1
08a	Osteosarcoma				2	2	8%	100%				27.9	9.2	8.1
08b	Chondrosarcoma													
08c	Ewing, related bone sarcoma													
08d	Other spec. malig. bone													
08e	Unspec. malig. bone													
09	SOFT TISSUE, EXTRAOSS.SARCOMA		2			2	8%	100%		33			9.2	10.2
09a	Rhabdomyosarcoma		2			2	8%	100%		33			9.2	10.2
09b	Fibrosarc,periph.nerve sheath													
09c	Kaposi sarcoma													
09d	Oth.spec.soft tissue sarcoma													
09e	Unspec.soft tissue sarcoma													
10	GERM CELL,TROPHOBLAST,GONAD	1				1	4%	100%	67.1				4.6	5.2
10a	Intracranial/spinal germ cell													
10b	Malig.extracran/gonad germ cell													
10c	Malignant gonadal germ cell	1				1	4%	100%	67.1				4.6	5.2
10d	Gonadal carcinomas													
10e	Other malignant gonadal													
11	MALIG.EPITHELIAL/MELANOMA				1	1	4%	100%				13.9	4.6	4
11a	Adrenocortical carcinoma													
11b	Thyroid carcinoma				1	1	4%	100%				13.9	4.6	4
11c	Nasopharyngeal carcinoma													
11d	Malignant melanoma													
11e	Skin carcinoma													
11f	Oth./unspec.carcinoma													
12	OTHER/UNSPEC.MALIG.NEOPLASM			1		1	4%	100%			14.2		4.6	4.6
12a	Other spec. malignant													
12b	Other unspec. malignant			1		1	4%	100%			14.2		4.6	4.6
	Total	1	10	6	9	26	100%		67.1	165	85.4	126	119.6	120

International Classification for Childhood Cancer

Female		NUMBER OF CASES					FREQUENCY		RATES PER MILLION					
ICCC		0	1-4	5-9	10-14	All	All	Group	0	1-4	5-9	10-14	Crude	ASR
01	LEUKAEMIA,MYELOPRO/MYELODYS.DIS.		5	2		7	41%	100%		86.6	30.2		33.9	36.6
01a	Lymphoid leukaemia		4	2		6	35%	86%		69.3	30.2		29.1	31.2
01b	Acute myeloid leukaemia		1			1	6%	14%		17.3			4.8	5.4
01c	Chronic myeloproliferative													
01d	Myelodysplas syn, myeloprolif.													
01e	Other/unspec leukaemia													
02	LYMPHOMAS, RETICULOENDOTHELIAL				2	2	12%	100%				29.3	9.7	8.5
02a	Hodgkin lymphoma				2	2	12%	100%				29.3	9.7	8.5
02b	NHL (not Burkitt)													
02c	Burkitt lymphoma													
02d	Misc lymphoreticular													
02e	Unspecified lymphoma													
03	CNS, INTRACRANIAL/SPINAL	1		1		2	12%	100%	70.5		15.1		9.7	10.3
03a	Ependymoma, choroid plexus													
03b	Astrocytoma													
03c	Intracranial/spinal embryonal													
03d	Other glioma	1		1		2	12%	100%	70.5		15.1		9.7	10.3
03e	Oth.spec.intracranial/spinal													
03f	Unspec.intracranial/spinal													
04	NEUROBLASTOMA,PER.NERV.CELL													
04a	Neuro/ganglioneuroblastoma													
04b	Other periph.nervous cell													
05	RETINOBLASTOMA													
06	RENAL TUMOUR		1			1	6%	100%		17.3			4.8	5.4
06a	Nephroblastoma, non-epithel.renal		1			1	6%	100%		17.3			4.8	5.4
06b	Renal carcinomas													
06c	Unspec.malig.renal													
07	HEPATIC TUMOUR													
07a	Hepatoblastoma													
07b	Hepatic carcinoma													
07c	Unspec.malig.hepatic													
08	MALIGNANT BONE TUMOUR				1	1	6%	100%				14.6	4.8	4.3
08a	Osteosarcoma				1	1	6%	100%				14.6	4.8	4.3
08b	Chondrosarcoma													
08c	Ewing, related bone sarcoma													
08d	Other spec. malig. bone													
08e	Unspec. malig. bone													
09	SOFT TISSUE, EXTRAOSS.SARCOMA			1	1	2	12%	100%			15.1	14.6	9.7	9.1
09a	Rhabdomyosarcoma			1		1	6%	50%			15.1		4.8	4.9
09b	Fibrosarc,periph.nerve sheath													
09c	Kaposi sarcoma													
09d	Oth.spec.soft tissue sarcoma													
09e	Unspec.soft tissue sarcoma				1	1	6%	50%				14.6	4.8	4.3
10	GERM CELL,TROPHOBLAST,GONAD													
10a	Intracranial/spinal germ cell													
10b	Malig.extracran/gonad germ cell													
10c	Malignant gonadal germ cell													
10d	Gonadal carcinomas													
10e	Other malignant gonadal													
11	MALIG.EPITHELIAL/MELANOMA				2	2	12%	100%				29.3	9.7	8.5
11a	Adrenocortical carcinoma													
11b	Thyroid carcinoma				2	2	12%	100%				29.3	9.7	8.5
11c	Nasopharyngeal carcinoma													
11d	Malignant melanoma													
11e	Skin carcinoma													
11f	Oth./unspec.carcinoma													
12	OTHER/UNSPEC.MALIG.NEOPLASM													
12a	Other spec. malignant													
12b	Other unspec. malignant													
	Total	1	6	4	6	17	100%		70.5	104	60.5	87.9	82.4	82.7

APPENDIX V. Cyprus Incidence numbers and rates 2011-2013, all ages

Incidence Tables
CanReg4 29/08/2016

CYPRUS2011-2013

Date : 29/08/2013
Source : Revised census 2011

Filter : Beha=3 and RecS=1 and (Restat=1 or Restat=9)

Standard pop. : World

Ages	Male	Female	WSP
0-4	25146	23963	12000
5-9	23411	22039	10000
10-14	23901	22752	9000
15-19	29990	28548	9000
20-24	35712	34415	8000
25-29	36650	37651	8000
30-34	33611	37028	6000
35-39	28331	33684	6000
40-44	27020	32006	6000
45-49	27197	30179	6000
50-54	27909	29271	5000
55-59	24692	25274	4000
60-64	23109	23863	4000
65-69	17900	19234	3000
70-74	14210	15668	2000
75-79	9929	12103	1000
80-84	6154	8513	500
85 +	4318	6582	500
???	0	0	
Total:	419190	442773	100000

Incidence date range:

From 01/01/2011
To 31/12/2013

NUMBER OF CASES - Male

Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	% of Total	ICD-10
Lip	8										2		1	3			1	1			0.2%	C00
Tongue	25									3		2	5	3	3	3	2	2		2	0.5%	C01-C02
Mouth	16	2									2		2	2	3	2	1	2			0.3%	C03-C06
Salivary glands	14	1											1	1	1	1	1	5	1	2	0.3%	C07-C08
Tonsil	8											1	3	2	1			1			0.2%	C09
Other Oropharynx	6										1	1				4					0.1%	C10
Nasopharynx	6									1		1	1		1	1		1			0.1%	C11
Hypopharynx	2												1		1							C12-C13
Pharynx unspec.																						C14
Oesophagus	17									1			1	4	2	2	4	2		1	0.3%	C15
Stomach	147			1				1		3	2	5	10	14	29	21	23	18	9	11	2.9%	C16
Small intestine	8									1				3		2		2			0.2%	C17
Colon	443	4						3	3	3	4	11	25	48	43	67	75	64	55	38	8.8%	C18
Rectum	213								1	2	2	5	15	22	33	30	39	32	18	14	4.2%	C19-C20
Anus	1													1								C21
Liver	100										2	2	7	6	12	13	18	20	9	11	2.0%	C22
Gallbladder etc.	39						1					1	1	5	2	6	8	4	8	3	0.8%	C23-C24
Pancreas	136	1									4	6	6	16	19	19	18	29	8	10	2.7%	C25
Nose, sinuses etc.	7									1			1		1		2	1		1	0.1%	C30-C31
Larynx	85											4	9	17	11	15	13	7	5	4	1.7%	C32
Trachea,Bronchus,Lung	717	2				1			3	2	11	10	39	63	104	142	139	104	59	38	14.2%	C33-C34
Other Thoracic organs	7										1	2		1	1			1		1	0.1%	C37-C38
Bone	13				2	1	2		1		1				1	1	2	1		1	0.3%	C40-C41
Melanoma of Skin	105	5				2	4	1	5	2	6	5	6	7	13	12	10	12	7	8	2.1%	C43
Other Skin																						C44
Mesothelioma	23												1	1	3	5	4	4	2	3	0.5%	C45
Kaposi sarcoma	5											2		1				1		1	0.1%	C46
Connective,Soft tissue	32		1					2	1	2	1		4	3		4	3	7	2	2	0.6%	C47;C49
Breast	22									1		1	1	3	5	2	3	3	1	2	0.4%	C50
Penis	19							1			2	1		2	1	6		2	3	1	0.4%	C60
Prostate	1458	60									1	12	38	91	188	278	338	242	118	92	28.8%	C61
Testis	104	2				10	14	18	17	18	10	7		2	4	1			1		2.1%	C62
Other male genital	1							1														C63
Kidney	117				1				1	5	2	2	11	15	15	17	19	16	8	5	2.3%	C64
Renal Pelvis	5															4		1			0.1%	C65
Ureter	4														1	1	1	1			0.1%	C66
Bladder	383	7							2	5	5	8	17	23	54	63	68	53	50	28	7.6%	C67
Other Urinary organs	3	1																	1	1	0.1%	C68
Eye	5		1												2		1			1	0.1%	C69
Brain, Nervous system	80		1		2	1	2	1	4		5	4	14	8	9	13	9	4	2	1	1.6%	C70-C72
Thyroid	134				1	4	7	12	10	13	16	14	14	11	12	8	8	3		1	2.6%	C73
Adrenal gland	2													1		1						C74
Other Endocrine	1													1								C75
Hodgkin disease	45			1		5	4	6	9	4	2	6	3	1		2	2				0.9%	C81
Non-Hodgkin lymphoma	190		1		1	1	1	4	4	9	6	9	19	20	25	31	15	24	14	6	3.8%	C82-C85;C96
Immunoproliferative dis.	1													1								C88
Multiple Myeloma	66	1									1	3	3	6	7	8	6	12	13	6	1.3%	C90
Lymphoid Leukaemia	76		6	3	2	4			1		1	4	4	7	14	6	8	4	6	6	1.5%	C91
Myeloid Leukaemia	50			1		2	2	4		1	3	2		3	7	3	8	3	7	4	1.0%	C92-C94
Leukaemia unspec.	15										1				2	2	1	4	1	4	0.3%	C95
Other & unspecified	96	1					1		1		1		7	6	8	15	10	12	18	16	1.9%	Other
All sites Total	5060	87	10	6	9	31	38	54	63	77	95	131	270	424	638	811	860	705	426	325	100%	All
All sites but C44	5060	87	10	6	9	31	38	54	63	77	95	131	270	424	638	811	860	705	426	325	100%	Not C44

NUMBER OF CASES - Female

Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	% of Total	ICD-10
Lip	2																			2		C00
Tongue	16								1	1	1	2	3		3	1		2	1	1	0.3%	C01-C02
Mouth	8	1							1	1				2		1		1	1		0.2%	C03-C06
Salivary glands	10											1	1	3		1		1	2	1	0.2%	C07-C08
Tonsil	5												2	2			1				0.1%	C09
Other Oropharynx																						C10
Nasopharynx	1															1						C11
Hypopharynx	1												1									C12-C13
Pharynx unspec.																						C14
Oesophagus	5													1	2	2					0.1%	C15
Stomach	111							1			1	6	5	12	12	8	14	21	21	10	2.4%	C16
Small intestine	5													2		1	1		1		0.1%	C17
Colon	345	9				1			2	6	16	16	27	26	33	37	49	44	50	29	7.4%	C18
Rectum	98						1		1		2	5	4	7	15	12	16	12	11	12	2.1%	C19-C20
Anus	11	1										1			3	2	2		2		0.2%	C21
Liver	54											3	3	2	4	8	7	10	4	13	1.2%	C22
Gallbladder etc.	43										2		4	5	2	4	11	7	5	3	0.9%	C23-C24
Pancreas	88										3	3	9	6	9	15	12	13	8	10	1.9%	C25
Nose, sinuses etc.	2								1										1			C30-C31
Larynx	6									1		3			1	1					0.1%	C32
Trachea,Bronchus,Lung	199	1						2	2	2	6	8	16	18	25	37	31	19	18	14	4.3%	C33-C34
Other Thoracic organs	6					1				1				1	2			1			0.1%	C37-C38
Bone	10			1	1	1	1				1	1		1	1	1	1				0.2%	C40-C41
Melanoma of Skin	92	3						2	1	3	12	11	4	10	9	13	8	5	9	2	2.0%	C43
Other Skin																						C44
Mesothelioma	10													1	2	1	3	1	1	1	0.2%	C45
Kaposi sarcoma	2																1			1		C46
Connective,Soft tissue	36				1		3	3	2	3	2	2	4	2	3	3		5	2	1	0.8%	C47;C49
Breast	1600	7						6	29	69	128	176	193	176	209	203	146	109	87	62	34.5%	C50
Vulva	27	1											2	2	2	5	3	2	4	6	0.6%	C51
Vagina	5												1		1			1		2	0.1%	C52
Cervix Uteri	101						1	4	5	12	14	23	8	11	6	5	5	3	4		2.2%	C53
Corpus Uteri	276	2							2		6	11	32	38	40	51	39	26	25	4	5.9%	C54
Uterus unspec.	12											1	1	2	2	1			1	4	0.3%	C55
Ovary	173					4		1	3	4	4	12	18	20	30	19	17	19	13	9	3.7%	C56
Other Female Genital	4												2	1						1	0.1%	C57
Placenta																						C58
Kidney	75		1				1	2	2		3	6	10	7	10	7	8	11	4	3	1.6%	C64
Renal Pelvis	2														1				1			C65
Ureter	2															1				1		C66
Bladder	71	3									3		3	4	3	6	8	13	12	16	1.5%	C67
Other Urinary organs																						C68
Eye	7									1		1		1	1		1			2	0.2%	C69
Brain, Nervous system	67		1	1			2	1	1	4	3	4	2	8	5	7	10	8	8	2	1.4%	C70-C72
Thyroid	547				2	9	21	46	37	58	62	54	80	61	56	34	19	6	1	1	11.8%	C73
Adrenal gland	2								1						1							C74
Other Endocrine																						C75
Hodgkin disease	61	1			2	5	9	9	6	9		2	3	4	4	2	1	2	1	1	1.3%	C81
Non-Hodgkin lymphoma	184	1					2	5	5	5	4	6	17	16	20	21	28	24	16	14	4.0%	C82-C85;C96
Immunoproliferative dis.	2																		2			C88
Multiple Myeloma	53										1	6	3	4	7	8	8	10	4	2	1.1%	C90
Lymphoid Leukaemia	56		4	2		4		1	1		3	2	4	2	5	5	5	7	5	6	1.2%	C91
Myeloid Leukaemia	50		1				1		4	2	1	3	1	4	2		10	10	5	6	1.1%	C92-C94
Leukaemia unspec.	13												2				2	2	2	5	0.3%	C95
Other & unspecified	83	1						1	1		1		4	2	12	8	12	11	12	18	1.8%	Other
All sites Total	4639	31	7	4	6	25	42	84	108	182	279	369	469	464	543	532	479	406	344	265	100%	All
All sites but C44	4639	31	7	4	6	25	42	84	108	182	279	369	469	464	543	532	479	406	344	265	100%	Not C44

INCIDENCE RATES - Male

Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude Rate	ASR World	ICD-10
Lip	8										2.5		1.2	4			2.3	3.4			0.6	0.5	C00
Tongue	25									3.5		2.5	6	4	4.3	5.6	4.7	6.7		15.4	2	1.4	C01-C02
Mouth	16	2									2.5		2.4	2.7	4.3	3.7	2.3	6.7			1.3	0.9	C03-C06
Salivary glands	14	1											1.2	1.3	1.4	1.9	2.3	16.8	5.4	15.4	1.1	0.6	C07-C08
Tonsil	8											1.2	3.6	2.7	1.4			3.4			0.6	0.5	C09
Other Oropharynx	6										1.2	1.2				7.4					0.5	0.4	C10
Nasopharynx	6									1.2		1.2	1.2		1.4	1.9		3.4			0.5	0.4	C11
Hypopharynx	2												1.2		1.4						0.2	0.1	C12-C13
Pharynx unspec.																							C14
Oesophagus	17									1.2			1.2	5.4	2.9	3.7	9.4	6.7		7.7	1.4	0.9	C15
Stomach	147			1				0.9		3.5	2.5	6.1	12	19	42	39.1	53.9	60.4	48.7	84.9	11.7	7.5	C16
Small intestine	8									1.2				4		3.7		6.7			0.6	0.4	C17
Colon	443	4						2.7	3	3.5	4.9	14	30	65	62	125	176	215	298	293	35.2	20.8	C18
Rectum	213								1	2.4	2.5	6.1	18	30	48	55.9	91.5	107	97.5	108	16.9	10.3	C19-C20
Anus	1													1.3							0.1	0.1	C21
Liver	100										2.5	2.5	8.4	8.1	17	24.2	42.2	67.1	48.7	84.9	8	4.6	C22
Gallbladder etc.	39						0.9					1.2	1.2	6.7	2.9	11.2	18.8	13.4	43.3	23.2	3.1	1.8	C23-C24
Pancreas	136	1									4.9	7.4	7.2	22	27	35.4	42.2	97.3	43.3	77.2	10.8	6.6	C25
Nose, sinuses etc.	7									1.2			1.2		1.4		4.7	3.4		7.7	0.6	0.4	C30-C31
Larynx	85											4.9	11	23	16	27.9	30.5	23.5	27.1	30.9	6.8	4.4	C32
Trachea,Bronchus,Lung	717	2				1.1			3	2.4	14	12	47	85	150	264	326	349	320	293	57	34.8	C33-C34
Other Thoracic organs	7										1.2	2.5		1.3	1.4			3.4		7.7	0.6	0.4	C37-C38
Bone	13				2.8	1.1	1.9		1		1.2				1.4	1.9	4.7	3.4		7.7	1	0.9	C40-C41
Melanoma of Skin	105	5				2.2	3.7	0.9	5	2.4	7.4	6.1	7.2	9.4	19	22.3	23.5	40.3	37.9	61.7	8.3	5.6	C43
Other Skin																							C44
Mesothelioma	23												1.2	1.3	4.3	9.3	9.4	13.4	10.8	23.2	1.8	1.1	C45
Kaposi sarcoma	5											2.5		1.3				3.4		7.7	0.4	0.3	C46
Connective,Soft tissue	32		1					1.8	1	2.4	1.2		4.8	4		7.4	7	23.5	10.8	15.4	2.5	1.7	C47;C49
Breast	22									1.2		1.2	1.2	4	7.2	3.7	7	10.1	5.4	15.4	1.7	1.1	C50
Penis	19							0.9			2.5	1.2		2.7	1.4	11.2		6.7	16.2	7.7	1.5	1	C60
Prostate	1458	60									1.2	15	45	123	271	518	793	812	639	710	115.9	68	C61
Testis	104	2				11	13	16	17	21	12	8.6		2.7	5.8	1.9			5.4		8.3	7.5	C62
Other male genital	1							0.9													0.1	0.1	C63
Kidney	117				1.4				1	5.9	2.5	2.5	13	20	22	31.7	44.6	53.7	43.3	38.6	9.3	6	C64
Renal Pelvis	5															7.4		3.4			0.4	0.3	C65
Ureter	4														1.4	1.9	2.3	3.4			0.3	0.2	C66
Bladder	383	7							2	5.9	6.2	9.8	20	31	78	117	160	178	271	216	30.4	18.1	C67
Other Urinary organs	3	1																	5.4	7.7	0.2	0.1	C68
Eye	5		1												2.9		2.3			7.7	0.4	0.4	C69
Brain, Nervous system	80		1		2.8	1.1	1.9	0.9	4		6.2	4.9	17	11	13	24.2	21.1	13.4	10.8	7.7	6.4	4.8	C70-C72
Thyroid	134				1.4	4.4	6.5	11	9.9	15	20	17	17	15	17	14.9	18.8	10.1		7.7	10.7	8.7	C73
Adrenal gland	2													1.3		1.9					0.2	0.1	C74
Other Endocrine	1													1.3							0.1	0.1	C75
Hodgkin disease	45			1		5.6	3.7	5.5	8.9	4.7	2.5	7.4	3.6	1.3		3.7	4.7				3.6	3.2	C81
Non-Hodgkin lymphoma	190		1		1.4	1.1	0.9	3.6	4	11	7.4	11	23	27	36	57.7	35.2	80.6	75.8	46.3	15.1	10.2	C82-C85;C96
Immunoproliferative dis.	1													1.3							0.1	0.1	C88
Multiple Myeloma	66	1									1.2	3.7	3.6	8.1	10	14.9	14.1	40.3	70.4	46.3	5.2	3	C90
Lymphoid Leukaemia	76		8	4	2.8	4.4			1		1.2	4.9	4.8	9.4	20	11.2	18.8	13.4	32.5	46.3	6	5.1	C91
Myeloid Leukaemia	50			1		2.2	1.9	3.6		1.2	3.7	2.5		4	10	5.6	18.8	10.1	37.9	30.9	4	2.8	C92-C94
Leukaemia unspec.	15										1.2				2.9	3.7	2.3	13.4	5.4	30.9	1.2	0.7	C95
Other & unspecified	96	1					0.9		1		1.2		8.4	8.1	12	27.9	23.5	40.3	97.5	124	7.6	4.3	Other
All sites Total	5060	87	13	9	13	34	35	49	62	91	117	161	322	572	920	1510	2017	2366	2307	2508	402.3	252.8	All
All sites but C44	5060	87	13	9	13	34	35	49	62	91	117	161	322	572	920	1510	2017	2366	2307	2508	402.3	252.8	Not C44

INCIDENCE RATES - Female

Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+	Crude Rate	ASR World	ICD-10
Lip	2																			10.1	0.2	0.1	C00
Tongue	16								0.9	1	1	2.2	3.4		4.2	1.7		5.5	3.9	5.1	1.2	0.8	C01-C02
Mouth	8	1							0.9	1				2.6		1.7		2.8	3.9		0.6	0.4	C03-C06
Salivary glands	10											1.1	1.1	4		1.7		2.8	7.8	5.1	0.8	0.4	C07-C08
Tonsil	5												2.3	2.6			2.1				0.4	0.3	C09
Other Oropharynx																							C10
Nasopharynx	1															1.7					0.1	0.1	C11
Hypopharynx	1												1.1								0.1	0.1	C12-C13
Pharynx unspec.																							C14
Oesophagus	5													1.3	2.8	3.5					0.4	0.3	C15
Stomach	111							0.9			1	6.6	5.7	16	17	13.9	29.8	57.8	82.2	50.6	8.4	4.4	C16
Small intestine	5													2.6		1.7	2.1		3.9		0.4	0.2	C17
Colon	345	9				1.2			1.8	5.9	17	18	31	34	46	64.1	104	121	196	147	26	14.7	C18
Rectum	98						1		0.9		2.1	5.5	4.6	9.2	21	20.8	34	33	43.1	60.8	7.4	4.2	C19-C20
Anus	11	1										1.1			4.2	3.5	4.3		7.8		0.8	0.5	C21
Liver	54											3.3	3.4	2.6	5.6	13.9	14.9	27.5	15.7	65.8	4.1	2.1	C22
Gallbladder etc.	43										2.1		4.6	6.6	2.8	6.9	23.4	19.3	19.6	15.2	3.2	1.8	C23-C24
Pancreas	88										3.1	3.3	10	7.9	13	26	25.5	35.8	31.3	50.6	6.6	3.8	C25
Nose, sinuses etc.	2								0.9										3.9		0.2	0.1	C30-C31
Larynx	6									1		3.3			1.4	1.7					0.5	0.4	C32
Trachea,Bronchus,Lung	199	1						1.8	1.8	2	6.2	8.8	18	24	35	64.1	65.9	52.3	70.5	70.9	15	9	C33-C34
Other Thoracic organs	6					1.2				1				1.3	2.8			2.8			0.5	0.4	C37-C38
Bone	10			2	1.5	1.2	1				1	1.1		1.3	1.4	1.7	2.1				0.8	0.8	C40-C41
Melanoma of Skin	92	3						1.8	0.9	3	13	12	4.6	13	13	22.5	17	13.8	35.2	10.1	6.9	4.6	C43
Other Skin																							C44
Mesothelioma	10													1.3	2.8	1.7	6.4	2.8	3.9	5.1	0.8	0.4	C45
Kaposi sarcoma	2																2.1			5.1	0.2	0.1	C46
Connective,Soft tissue	36				1.5		2.9	2.7	1.8	3	2.1	2.2	4.6	2.6	4.2	5.2		13.8	7.8	5.1	2.7	2	C47;C49
Breast	1600	7						5.3	26	68	133	194	220	232	292	352	311	300	341	314	120.4	81.1	C50
Vulva	27	1											2.3	2.6	2.8	8.7	6.4	5.5	15.7	30.4	2	1	C51
Vagina	5												1.1		1.4			2.8		10.1	0.4	0.2	C52
Cervix Uteri	101						1	3.5	4.5	12	15	25	9.1	15	8.4	8.7	10.6	8.3	15.7		7.6	5.7	C53
Corpus Uteri	276	2							1.8		6.2	12	36	50	56	88.4	83	71.6	97.9	20.3	20.8	13	C54
Uterus unspec.	12											1.1	1.1	2.6	2.8	1.7			3.9	20.3	0.9	0.5	C55
Ovary	173					4.7		0.9	2.7	4	4.2	13	21	26	42	32.9	36.2	52.3	50.9	45.6	13	8.4	C56
Other Female Genital	4												2.3	1.3						5.1	0.3	0.2	C57
Placenta																							C58
Kidney	75		1				1	1.8	1.8		3.1	6.6	11	9.2	14	12.1	17	30.3	15.7	15.2	5.6	3.7	C64
Renal Pelvis	2														1.4				3.9		0.2	0.1	C65
Ureter	2															1.7				5.1	0.2	0.1	C66
Bladder	71	3									3.1		3.4	5.3	4.2	10.4	17	35.8	47	81	5.3	2.5	C67
Other Urinary organs																							C68
Eye	7									1		1.1		1.3	1.4		2.1			10.1	0.5	0.3	C69
Brain, Nervous system	67		1	2			1.9	0.9	0.9	4	3.1	4.4	2.3	11	7	12.1	21.3	22	31.3	10.1	5	3.3	C70-C72
Thyroid	547				2.9	11	20	41	33	57	65	60	91	80	78	58.9	40.4	16.5	3.9	5.1	41.2	32.7	C73
Adrenal gland	2								0.9						1.4						0.2	0.1	C74
Other Endocrine																							C75
Hodgkin disease	61	1			2.9	5.8	8.7	8	5.4	8.9		2.2	3.4	5.3	5.6	3.5	2.1	5.5	3.9	5.1	4.6	4	C81
Non-Hodgkin lymphoma	184	1					1.9	4.4	4.5	4.9	4.2	6.6	19	21	28	36.4	59.6	66.1	62.6	70.9	13.8	8.3	C82-C85;C96
Immunoproliferative dis.	2																		7.8		0.2		C88
Multiple Myeloma	53										1	6.6	3.4	5.3	9.8	13.9	17	27.5	15.7	10.1	4	2.4	C90
Lymphoid Leukaemia	56		6	3		4.7		0.9	0.9		3.1	2.2	4.6	2.6	7	8.7	10.6	19.3	19.6	30.4	4.2	3.4	C91
Myeloid Leukaemia	50		1				1		3.6	2	1	3.3	1.1	5.3	2.8		21.3	27.5	19.6	30.4	3.8	2.2	C92-C94
Leukaemia unspec.	13												2.3				4.3	5.5	7.8	25.3	1	0.4	C95
Other & unspecified	83	1						0.9	0.9		1		4.6	2.6	17	13.9	25.5	30.3	47	91.1	6.2	3.1	Other
All sites Total	4639	31	10	6	9	29	41	74	97	180	291	407	534	612	758	922	1019	1118	1347	1342	349.2	228.6	All
All sites but C44	4639	31	10	6	9	29	41	74	97	180	291	407	534	612	758	922	1019	1118	1347	1342	349.2	228.6	Not C44

MECC JOINT REGISTRATION PROJECT

Cyprus Cancer Registry (CyCR)

Progress Report for 2016

(Data 2011-2013)